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Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically 
important swine diseases worldwide that leads to severe reproductive failure in sows and high 
mortality in young pigs. Vaccination is currently the most effective way to control this disease. 
The protection ability provided by vaccines however is limited due to the large diversity of field 
PRRSV strains. In chapter 2, we compared immune responses induced by vaccination and/or 
PRRSV infection by using IngelVac® Modified Live PRRSV vaccine (MLV), its parental strain 
VR-2332, and the heterologous KS-06 strain. Our results showed that MLV provide complete 
protection to homologous virus and partial protection to heterologous challenge. The protection 
was associated with the levels of PRRSV neutralizing antibodies at the time of challenge. 
 
Besides developing new vaccines to combat PRRSV, adjuvants have been applied to PRRSV 
MLV vaccines to induce vaccination-mediated cross-protection against genetically dissimilar 
PRRSV strains. In chapter 3, we demonstrated that a commercial Montanide
TM
 Gel01ST 
adjuvant provides enhanced protection to homologous PRRSV infection by regulating the 
production of PRRSV-specific antibodies. In chapter 4, we tested a novel peptide nanofiber 
hydrogel acting as a potent adjuvant for PRRSV MLV vaccines. We found that the hydrogel 
adjuvant enhanced vaccine efficacy by developing of higher titers of neutralizing antibodies and 
stronger IFN-γ cellular immune responses.  
 
Chinese highly pathogenic PRRSV (HP-PRRSV) variants were isolated in 2006 and they belong 
to genotype 2 of PRRSV. Compared with classic PRRSV, HP-PRRSV is characterized by robust 
proliferation ability and high morbidity/mortality with all ages of pigs. In chapter 5, we 
compared the difference of immune responses elicited by HV-PRRSV, a Chinese HP-PRRSV, 
and a US virulent strain of PRRSV NADC-20. Traditional PRRSV MLV vaccines developed in 
US offer no protection to HP-PRRSV. Vaccines specific to HP-PRRSV strains available in 
China provide protection to HP-PRRSV. In chapter 6, we demonstrated that pigs challenged with 
US NADC-20 strain were protected by vaccination with Chinese MLV HP-PRRSV vaccines. 
The availability of Chinese HP-PRRSV vaccines in North America may act to increase the 
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Chapter 1 - Introduction to PRRSV 
 
 1.1. History of PRRS 
Porcine reproductive and respiratory syndrome (PRRS) was first characterized in 1987 in the 
United States of America with a clinical presentation of severe reproductive losses in late 
gestational sows and perinatal losses and respiratory distress of piglets [1]. The etiological agent, 
PRRS virus (PRRSV), was identified in Europe in 1991 and termed Lelystad virus [2]. PRRSV 
was subsequently isolated in the US and assigned the name VR-2332 [3]. Since then, PRRS has 
become an endemic disease in the global swine industry and has led to huge economic losses in 
the pork industry [4]. 
 
PRRSV seems to evolve by random mutation and intragenic recombination events that led to the 
emergence of different variants with high pathogenicity to pigs, such as the recent outbreak of 
Chinese highly pathogenic PRRSV in China in 2006, the high virulent 1-18-2 strain in U.S. in 
2007, and east European subtype 3 PRRSV isolate Lena strain in Europe  [5-7]. Classic PRRSV 
causes mild clinical symptoms and leads to abortion in sows and death of piglets. In contrast, 
these highly pathogenic strains of PRRSV lead to increased tissue atrophy and greater morbidity 
and mortality rate in all ages of pigs [5].  
 
 1.2. PRRS virus and strain heterogeneity 
PRRSV is a small, enveloped positive-strand RNA virus, which belongs to the family 
Arteriviridae in the order of the Nidovirales that include members of the Coronaviridae and 
Roniviridae families [8]. The family Arteriviridae also comprises three other viruses: equine 
arteritis virus (EAV), simian hemorrhagic fever virus (SHFV), and lactate dehydrogenase 






PRRSV isolates are divided into two distinct genotypes: the European (Type 1) and North 
American (Type 2). The two genotypes of PRRSV cause the same disease symptoms but are 
antigenically different. The two genotypes differ approximately 60% from each other at the 
genomic sequence level [9]. Within the European PRRSV genotype, three subtypes have been 
further delineated based on ORF5 and ORF7, namely a Pan-European subtype 1, East European 
subtype 2, and subtype 3 [10]. 
 
PRRSV is a roughly spherical virion with a diameter of 50-60 nm and buoyant densities of 1.13-
1.17 g cm
-3
 in sucrose [11]. PRRSV is one of the most rapidly evolving viruses and its 
evolutionary rate of 1-3×10
-2 
 substitution per year is the highest among RNA viruses reported so 
far [12]. Field isolates of PRRSV exhibit considerable sequence heterogeneity of up to 20% [13]. 
Among these structural proteins, the major envelope protein GP5 is the most variable protein, 
with 50-100% amino acid identities among different field isolates [14], most likely because GP5 
induces neutralizing antibodies and therefore exposed to selective antibody pressure. NSP2 is the 
most variable nonstructural protein among 14 nonstructural proteins. As the largest PRRSV 
protein, NSP2 is tolerant for mutations, deletions, and insertions, which further contribute to the 
variability of NSP2 [15]. PRRSV NSP2 is an immune-dominant protein with the ability to 
induce a strong humoral antibody and cellular immune response [16]. Like the variability of 
GP5, natural deletions and hyper-variability of NSP2 may also work as a strategy that virus 
compromise host immunity. All the above facts make it difficult to develop efficient vaccines 
with cross-protection to different field isolates.  
 1.3. PRRSV genome organization 
The PRRSV genome is a single-stranded, positive-sense RNA, which is approximately 15 kb in 
length and consists of a 5’-untranslated region (UTR), nine open reading frames (ORFs), ORF1a, 
ORF1b, ORF2a, ORF2b, ORF3, ORF4, ORF5, ORF6, and ORF7, followed by a 3’-UTR and a 
poly (A) tail [11]. The ORF1a and ORF1b located in the 5’-proximal part consists of 
approximately 75% of the genome and encodes 14 putative non-structural proteins which are 
mostly involved in genome replication and subgenomic mRNA transcription. These NSPs work 
as viral proteases (NSP1α, NSP1β, NSP2 and NSP4), a RNA-dependent RNA polymerase 





NSPs also modulate host immune response for more efficient viral replication. NSP2 contains 
several immunodominant B-cell epitopes that are dispensable for virus replication [18]. NSP1α, 
NSP1β, NSP2, NSP4 and NSP11 attenuate type I IFN response by inhibiting the activation of the 
interferon beta (IFN-β) promoter [19]. 
 
The 3’-proximal part of the genome encodes seven PRRSV structural proteins that are translated 
from a 3’-coterminal nested set of six subgenomic mRNAs. ORF2a, ORF2b, and ORFs 3-7 
encode viral structural proteins GP2a, GP2b, GP3, GP4, GP5, M, and N, respectively[11]. Four 
of them are membrane-associated N-glycosylated proteins (GP2a, GP3, GP4 and GP5) and two 
are non-glycosylated membrane proteins (GP2b and M). The nucleocapsid protein (N) 
encapsulates the viral RNA genome. The GP5 and M proteins are the two major envelope 
proteins in PRRSV which exist as a disulfide-linked heterodimer in the virion [20]. The GP5 
protein is also the most abundant enveloped glycoprotein containing major neutralizing epitopes 
[21]. GP5a, this protein is encoded by an alternative reading frame of subgenomic mRNA GP5, 
responsible of recognizing the cell receptor in target cells [22]. Nucleocapsid protein, existing as 
a dimer, is highly immunogenic and serves as the main diagnostic protein to detect antibodies to 
PRRSV [23]. As for the minor proteins, GP2a, GP3 and GP4 form a structural trimer important 
for viral tropism and entry into cells [24]. Studies on PRRSV non-structural and structural 
proteins provide new insights on PRRSV biology and vaccine development. 
 
 1.4. PRRSV clinical and pathological aspects 
Clinical signs of PRRSV infection vary with the strains of virus. PRRSV causes piglets to 
develop clinical signs including dyspnea, anorexia, lethargy, cutaneous hyperemia, and 
decreased body weight gain [25]. The infection of PRRSV sometimes leads to reddish to blue 
discoloration and blotching of the skin, most often of the ears, which give PRRS the name of 
“Blue ear disease”. Subclinical infection often occurs in finishing pigs, boars, gilts and sows, and 
the clinical symptoms are mild. Pregnant sows infected pigs the clinical signs including 
infertility, lowered farrowing rates, increased abrogation rate in late gestation, and stillborn, 
mummified or weak live born piglets [26]. Sows seldom develop respiratory symptoms and they 





characterized by high body temperature (>41°C), rubefaction on the skin, respiratory disorder, 
and high morbidity (50-100%) and mortality (20-100%) in all age of affected pigs [27]. Most of 
infected pigs showed obvious respiratory distress such as sneezing, coughing, dyspnea, increased 
eye secretion, conjunctivitis, constipation and diarrhea. As for the infected pregnant sows, the 
abortion rate is more than 40%, and the mortality of sows is usually 10% [27]. 
 
PRRSV produces a multi-systemic infection in pigs, but gross lesions are usually only observed 
in respiratory and lymphoid tissues. PRRSV-infected pigs show mottled, tan and red lung and 
lymph nodes are moderately to severely enlarged and tan in color. Microscopic examination 
reveals moderate to severe multifocal interstitial pneumonia characterized by alveolar septal 
infiltration by a mixed population of mononuclear cells, hypertrophy and hyperplasia of 
pneumocytes and marked mixed inflammatory and necrotic alveolar exudate [26]. PRRSV has a 
tropism for macrophages and replicates mainly in macrophages of the lymphoid tissues and 
lungs in the acute phase of infection and persists in tonsil and lung macrophages. However, HP-
PRRSV exhibits more extensive tissue tropism than classic PRRSV [28]. Besides lymphoid 
tissues, immunohistochemistry examination shows that HP-PRRSV antigen can also be detected 
in the tissues including trachea, esophagus, liver, kidney, cerebellum, stomach, and intestine, 
which prove its high pathogenicity to pigs [29].  
 
 1.5. Host anti-PRRSV immunity 
PRRSV infection results in weak and delayed immune responses that lead to long-lasting viremia 
in the blood and lymphoid tissues. PRRSV circumvents the host immune response by 
suppression of type I interferon (IFN) production, generation of non-neutralizing antibodies in 
the early stage of infection and low titers of protective neutralizing antibody (NAb), and 
impaired T cell-mediated immune (CMI) response [30]. The study of mechanisms of PRRSV 
used to escape host immunity is still undergoing, and better understanding of these mechanisms 
facilitates to develop more robust vaccines to control PRRS.  
 
The innate immune response against PRRSV is very weak [19]. PRRSV does not induce IFN-α 





inflammatory cytokines and activation and recruitment of natural killer (NK) cells [31]. PRRSV 
infection also compromises the production of IFN-β at transcriptional and post-transcriptional 
level in macrophages and dendritic cells [32, 33]. PRRSV NSP1α and NSP1β were proposed to 
be major modulators of type I IFN cytokine expression in the early infectious process, and type I 
IFNs may be instrumental in effective induction of adaptive immunity and memory responses 
[17, 34-36]. For this reason, lack of type I interferon production is assumed to reduce the overall 
immune response.  
 
PRRSV also compromises the adaptive immunity by utilizing different mechanisms. A hallmark 
of the swine humoral response against PRRSV is the production of non-neutralizing antibodies 
detected early in the infection, followed by a low neutralizing antibody titer that is detected more 
than 3 weeks after infection [37]. These non-neutralizing antibodies are involved in antibody-
dependent enhancement (ADE) of PRRSV infection, which facilitate the entry of virus into 
target cells, leading to increased infectivity [38]. ADE may suppress the innate antiviral 
response, especially type I IFN system of the host [39]. Moreover, ADE enables the viruses to 
benefit from the anti-inflammatory and immunosuppressive environment created by autocrine 
and paracrine IL-10 production [40]. 
 
PRRSV neutralizing antibodies play a critical role in clearance of virus and are able to 
completely protect pigs against PRRSV re-infection [41]. As mentioned above, GP5 is the major 
structural protein that elicits the production of neutralizing Abs. Besides the high variability of 
GP5 protein among different strains of PRRSV, which leads to less cross-protective immunity, 
the presence of two decoy epitopes and glycan-shielding of the epitope critical for neutralization 
in GP5 protein were also proposed to explain the delay in NAb induction [42]. 
 
PRRSV infection results in a weak and delayed T cell mediated immune response that should be 
necessary for the elimination of the virus [43]. It has been shown that the induction of IFN-γ 
secreting cells, complementing neutralizing antibodies, provides partial protection against 
PRRSV [44,45]. However, the abundance of PRRSV-specific T cells and IFN-γ-secreting cells 
in infected pigs appears to be highly variable and has no apparent correlation with the viral load 





subpopulation producing IL-10 and TGF-β upon antigenic stimulation as a protection mechanism 
to reduce IFN-γ, TNF-α and IL-12 levels and suppress effector T cell activation and proliferation 
[46, 47]. Specific knowledge of porcine T-cell function and mechanisms of action in response to 
PRRSV infection is lacking due to the absence of tools and methods for selection and culture of 
antigen-specific T cells. 
 
 1.6. PRRSV vaccines  
Vaccination is the principal means used to control and treat PRRSV infection. Attenuation of 
virulent pathogens by cultivation in non-native conditions and the development of adjuvants 
provide tools to broaden the useful range of vaccines. The current commercial PRRSV vaccines 
include products containing live virus derived by cell culture attenuation of virulent field isolates 
and inactivated preparations of attenuated PRRSV strains. Some other experimental vaccines 
include inactivated preparation of multiple virulent isolates enriched with viral antigens, subunit 
vaccines expressing selected proteins, and next generation of PRRSV vaccines based on reverse 
genetics [48]. 
 
Commercially available vaccines have some limitations against PRRSV infection. Killed or 
subunit PRRSV vaccines have been less effective in prevention of both infection and disease 
[49]. The outcomes of the use of inactivated vaccines to prevent PRRSV infection are not 
promising. The current widely used modified live vaccines based on attenuated European or 
North American PRRSV strains provide decent protection against challenge with homologous 
isolates but very limit or no protection against heterologous viruses [45]. Moreover, modified 
live vaccines may allow virus shedding, and could revert generating virulent phenotypes [50]. 
For example, acute PRRS outbreak occurred in Danish herds vaccinated with an MLV, and the 
outbreak was linked to reversion of the vaccine virus to a pathogenic phenotype [51]. Therefore, 
the design of future vaccines must take the antigenic and genetic diversity of PRRSV into 
consideration or PRRS will remain difficult to control. 
 
PRRSV reverse genetics techniques provide a powerful tool to dissect the mechanism of PRRSV 





defined as the generation of viruses possessing a genome derived from cloned cDNAs (infectious 
clones). Compared with the current PRRSV vaccines, the next generation vaccines have reduced 
cost and time by bypassing the need of an RNA in-vitro-transcription step. To circumvent the 
limited heterologous protection in the field, chimeric cDNA clones derived from different 
distinct PRRSV strains were created, and the reciprocal chimeric viruses have less severe 
pathogenicity and show protection against challenge with parental heterologous strains [52]. 
Generation of a marker or DIVA (differentiating infected from vaccinated animals) PRRSV 
vaccine based on a deletion marker (i.e., an immunogenic marker absent from the vaccine strain 
but present in field strains) on the viral genome by reverse genetics system will allow for 
differentiation and be of great value for the control and eventual elimination of PRRSV [53, 54]. 
 
 1.7. PRRSV vaccine adjuvants 
Besides developing new vaccines to combat PRRSV, several types of adjuvants such as mineral 
oils and salts, bacterial products, cytokines, peptides and liposomes have been applied to killed 
or live modified PRRSV vaccines to induce vaccination-mediated cross-protection against 
genetically dissimilar PRRSV strains [55-59]. These adjuvants can enhance the immune 
responses by different mechanisms such as delivering the antigen slowly to the organism (depot 
effect), increased antigen uptake and presentation to antigen presenting cell, recruitment and 
activation of macrophages and lymphocytes, and stimulation of the production of cytokines and 
chemokines [60, 61]. Both MLV and killed PRRSV vaccines showed improved protection ability 
when they were combined with different types of adjuvants by the evidence of increment on 
neutralizing Ab production and reduction in viremia level and clinical signs, increased levels of 
proinflammatory cytokines and specific cell proliferation [62, 63].  
 
Adjuvants applied to PRRSV MLV vaccines have been reported recently. Mycobacterium 
tuberculosis whole cell lysate applied to PRRSV MLV vaccine as an adjuvant generated 
effective cross-protective immunity against PRRSV due to enhanced Th1-biased immune 
responses [62]. The commercial Montanide
TM
 class of flexible polymeric adjuvants combined 
with PRRSV MLV provided better protection to homologous viral challenge than MLV vaccine 





development of T-regulatory cells [64]. Pigs were equally protected from challenge  by 
vaccination with Montanide
TM 
Gel01 adjuvanted PRRSV MLV vaccine containing only 50% of 
the antigen load as 100% non-adjuvanted vaccine antigen load [65]. New types of adjuvants such 
as thermo-sensitive hydrogel have also been applied to PRRSV MLV vaccines. Our research 
group was the first to report that H9e peptide hydrogel, as an adjuvant for PRRSV MLV vaccine, 
can enhance vaccine efficacy against two different PRRSV strains by modulating both host 
humoral and cellular immune responses [66]. Therefore, use of adjuvants with current PRRSV 
vaccines may act as a necessary supplement to help vaccines to confer full antiviral immunity 
against heterologous challenges and to override the immune evasion strategies of PRRSV.  
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Chapter 2 - Comparison of host immune responses to homologous 





Abstract: Porcine reproductive and respiratory syndrome (PRRS) is a high-consequence animal 
disease with current vaccines providing limited protection to infection due to the high degree of 
genetic variation of field PRRS virus. Therefore, understanding host immune responses elicited 
by different PRRSV strains will facilitate the development of more effective vaccines. Using 
IngelVac® Modified Live PRRSV vaccine (MLV), its parental strain VR-2332, and the 
heterologous KS-06-72109 strain (a Kansas isolate of PRRSV), we compared immune responses 
induced by vaccination and/or PRRSV infection.  Our results showed that MLV can provide 
complete protection to homologous virus (VR-2332) and partial protection to heterologous (KS-
06) challenge. The protection was associated with the levels of PRRSV neutralizing antibodies at 
the time of challenge, with vaccinated pigs having higher titers to VR-2332 compared with KS-
06 strain. Challenge strain did not alter the cytokine expression profiles in the serum of 
vaccinated pigs or subpopulations of T cells. In contrast, higher frequencies of IFN-γ-secreting 
PBMCs were generated from pigs challenged with heterologous PRRSV in a recall response 
when PBMCs were restimulated with PRRSV. Thus, this study indicates that serum neutralizing 
antibody titers are associated with PRRSV vaccination-induced protection against homologous 
and heterologous challenge.  
 
 2.1. Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is an economically important pandemic 
disease characterized by reproductive failure in sows and respiratory disease in young pigs. A 
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recent study estimates that the total productivity losses in the U.S. swine industry due to PRRS is 
currently $664 million annually, an increase from the $560 million annual cost estimated in 2005 
[1]. This indicates that not only does PRRS have a significant financial impact on the pork 
industry, but also current strategies for reducing the burden of PRRS virus are not adequate.  
 
PRRS is caused by porcine reproductive and respiratory syndrome virus (PRRSV), which is a 
member of the genus Arterivirus, family Arteriviridae, and order Nidovirales. PRRSV is known 
to mutate rapidly in both in vitro cell culture models and in vivo in natural field infections [2]. 
The ability of PRRSV to mutate rapidly creates genetically extensive and antigenic diverse 
strains in both North American and European field isolates [3]. The high genetic mutation rate of 
PRRSV poses a challenge for PRRSV vaccine development [2]. Currently, both inactivated 
PRRSV vaccines and modified-live-virus (MLV) PRRSV vaccines are widely used to control the 
disease. However, inactivated vaccines as well as modified-live vaccines have been shown to be 
ineffective in providing protective immunity to heterologous strains of PRRSV at the herd level 
[4-7]. Therefore, development of a broadly protective PRRSV vaccine will be one of the most 
efficient solutions to control the prevalence of PRRS worldwide. 
 
It has been shown that pigs infected with PRRSV have inadequate immune responses, such as 
delayed onset of neutralizing antibody as well as weak interferon (IFN)-γ responses [2,8]. 
Development of different types of vaccines aiming to increase host immune response and get 
broader protection to various field PRRSV infections has been proposed [9]. Currently, PRRSV-
MLV is used to control the disease worldwide. However, the high incidence of genetic mutation 
during PRRSV transmission often results in vaccines based on strains of PPRSV isolated twenty 
years ago, such as MLV, having limited protection to new emerging viral strains. Disparity of 
immune responses elicited by different PRRSV strains was reported previously [10]. However, 
the role of humoral and cellular immune responses was not clearly elucidated in these reports 
with regard to the protection of virus challenge with different PRRSV strains. Therefore, 
dissecting the mechanisms of immune responses that are predictive of protection against 
heterologous PRRSV challenge will be valuable for the development of more efficacious 
vaccines. In this study, we investigated the differential profiles of host immune responses in 






 2.2. Materials and Methods 
 2.2.1. Cells and virus 
MARC-145 cells were maintained in Modified Eagle’s medium (MEM) supplemented with 7% 
fetal bovine serum (FBS) containing 100 U penicillin/ml and 100 μg streptomycin/ml at 37°C 
with 5% CO2. Virus stocks were prepared and titered in MARC-145 cells and stored in aliquots 
at -80°C until use. For virus infection and titration, MEM supplemented with 2% FBS was used. 
PRRS modified live virus vaccine (Ingelvac® PRRS MLV) was purchased from Boehringer 
Ingelheim Vetmedica Inc. PRRSV strains VR-2332, KS-06-72109 (KS-06) and NVSL97-7895 
have been described previously [11, 12]. 
 2.2.2. Pigs, vaccination and challenge 
Twenty conventional Large White-Duroc crossbred weaned specific-pathogen free piglets (3 
weeks of age) were divided into four groups and were kept in separate rooms within the Large 
Animal Research Center (LARC) facility, Kansas State University. These piglets were confirmed 
sera-negative for antibodies to PRRSV by ELISA and PRPSV-free in the blood by RT-PCR. 
Pigs were allowed to acclimate for an additional week before initiation of the experiment. During 
our study, all animals received food and water ad libitum. The first two groups were immunized 
intramuscularly on day post-vaccination (DPV) 0 with vaccine (PRRS-MLV, 1 x 10
6
 TCID50/ 
pig). The other two groups were used as control groups before challenge and remained 
unvaccinated (Fig. 2.1A).  After four weeks the pigs were challenged with 2 x 10
5
 TCID50/pig of 
VR-2332 or KS-06 PRRSV. Necropsy was performed at 14 days post challenge (DPC). Pigs 
were monitored for rectal temperature for the first 9 days after challenge and body weight once a 
week for the duration of this experiment. 
2.2.3. Collection of blood samples for analysis 
Blood was collected on DPV 0, 7, 14, 21, 28 and DPC 7 and 14. Serum was separated from 
clotted blood and preserved at -20°C. Serum was used for evaluation of viral titers, serum 
neutralizing antibody titers, PRRSV-specific ELISA antibody titers (Herdchek Porcine 





expression as described previously [12]. Peripheral blood mononuclear cells (PBMCs) were 
isolated from heparinized blood samples by Ficoll-Hypaque gradient centrifugation using 
Histopaque®-1077 (Sigma-Aldrich, St. Louis, MO). PBMCs were used for ELISpot assay and 
flow cytometry analysis as described previously [12]. 
 2.2.4. Gross lung lesion analysis 
Pigs were humanely euthanized on DPC 14 as approved by the Kansas State University 
Institutional Animal Use and Biosafety Committee. The lungs were macroscopically and 
microscopically evaluated as previously described [13].  Briefly, the dorsal and ventral surfaces 
of each lung lobe were given a score representing the approximate proportion that was 
consolidated. Individual lobe scores were used to determine an overall lung score representing 
the percentage of the total lung macroscopically pneumonic. Sections of each of the 4 lobes of 
the right lung were fixed in 10% buffered neutral formalin, paraffin-embedded, sectioned, and 
stained with hematoxylin and eosin (H & E).  Scoring of microscopic lung pathology was done 
in a blinded fashion by two veterinary pathologists in the Kansas State Veterinary Diagnostic 
Laboratory.  Grading was on a 4 point scale as previously described [13]. 
 2.2.5. Analysis of PRRSV circulating in the blood 
Total RNA was extracted from pig serum and one-step SyBR Green real-time PCR (Bio-Rad) 
was performed to evaluate the PRRSV ORF7 expression level as previously described [14]. For 
quantification, total RNA of a known TCID50 of virus was 10-fold serially diluted and was used 
to generate a standard curve. The virus quantities of unknown samples were determined by linear 
extrapolation of the Ct value plotted against the standard curve. 
 2.2.6. Virus neutralizing antibody titer 
Virus neutralizing antibody titers were assayed as previously described [12, 14]. Briefly, serum 
samples were heat inactivated (56°C, 30 min) and serially diluted before the titration. The serial 
dilutions of serum samples were mixed with equal volume of PRRSV strains: VR-2332, KS-06, 
or NVSL97-7895 containing 200 TCID50 of the virus. After incubation at 37°C for 1 h, the 
mixtures were transferred to MARC-145 monolayers in 96-well plates and incubated for an 
additional 72 h at 37°C in a humidified atmosphere containing 5% CO2. Cells were then 





calculated as the reciprocal of the highest serum dilution required to neutralize 200 TCID50 of 
PRRSV in 90% of the wells. 
 2.2.7. Analysis of PRRSV circulating in the blood 
Half million PBMCs were plated in enriched RPMI in a 96-well multiscreen plate (Millipore, 
Billerica, MA) pre-coated overnight with capture IFN-γ mAB (BD Pharmingen, San Diego, CA). 
PBMCs were re-stimulated with three different strains of PRRSV (VR-2332, KS-06 or NVSL97-
7895) at 0.1 MOI for 24 h at 37°C. IFN-γ-secreting cells were detected by biotinylated anti-pig 
IFN-γ detection antibody and visualized using the immunospot image analyzer (Cellular 
Technology, Cleveland, OH). The number of PRRSV-specific IFN-γ-secreting cells was 
calculated by “total IFN-γ-secreting cells after PRRSV re-stimulation” minus “total IFN-γ-
secreting cells after MARC-145 cell lysis re-stimulation”. Data were presented as the mean 
numbers of antigen-specific IFN-γ-secreting cells per 10
6
 PBMCs from duplicate wells of each 
sample. 
 2.2.8. Flow cytometry analysis 
Flow cytometry analysis was performed to determine different lymphocyte populations based on 






















anti-pig TcR1N4 antibody was purchased from VMRD (Pullman, WA), and the rest of the 
antibodies used in this study were purchased from BD Biosciences. Immuno-stained cells were 
acquired using a FACS Caliber (BD Biosciences) flow cytometer as described previously [12, 
14]. Briefly, PBMC was treated with 2% pig serum to block Fc receptors. Cells were then 
stained with an appropriate Ab which was either directly conjugated to a specific fluorochrome 
or with a purified Ab to pig specific immune cell surface marker (TcR1N4). For cells stained 
with a purified Ab, labeled cells were treated with anti-species isotype specific secondary Ab 
conjugated with fluorochrome. Finally, cells were fixed with 1% paraformaldehyde before flow 
cytometer reading. Percentages of each lymphocyte population were analyzed by 100,000 unique 





 2.2.9. Analysis of cytokine responses 
Pig sera were collected at DPC 7 to evaluate IL-4, IL-8, IL-10, IFN-γ, TNF-α (Life 
Technologies, Carlsbad, CA) and IFN-α (Abcam, Cambridge, MA) secretion profiles by ELISA. 
Procedures were performed as per the manufacturer’s instructions. For a given sample, the 
OD450 was then transformed to concentration by applying a linear regression formula calculated 
from the results of the standards provided in each kit. 
 2.2.10. Statistical analysis 
All data were expressed as the mean value of five pigs ± SEM. The differences in the level of 
body temperature, body weight, lung pathology score, humoral response, cytokine production 
and viremia among each group were determined by the one-way analysis of variance (ANOVA) 
followed by post-hoc Tukey’s test using SigmaPlot 11 software (Systat Software Inc., San Jose, 
CA). The difference in the percentage of different T cell subpopulations was determined by the 
paired t test using SigmaPlot 11 software. 
 
 2.3. Results 
2.3.1. Vaccination with PRRSV-MLV induced complete protection to homologous 
PRRSV challenge and partial protection to heterologous challenge 
To compare host immune responses to challenge by different PRRSV isolates, pigs were either 
vaccinated with PRRSV-MLV or a mock vaccine (PBS) on day 0 and then challenged with 
homologous VR-2332 or heterologous KS-06 PRRSV on day 28 (Fig.2.1A). Clinically, the mean 
body temperature of unvaccinated pigs challenged with the KS-06 strain of PRRSV was higher 
compared with that in the other three groups at DPC 4 (Fig. 2.1B).  The body weight of all pigs 
was tracked throughout the study and weights of all groups were similar during the vaccination 
phase. Interestingly, pigs vaccinated with MLV and challenged with VR-2332 had a slightly 
higher weight gain than that of the other groups on DPC 14 (data not shown). Unvaccinated pigs 
that were challenged with either VR-2332 or the KS-06 strain had higher lung lesion scores on 
DPC 14 compared with that in vaccinated pigs (Fig.2.1C). Vaccinated pigs challenged with VR-
2332 showed full protection against PRRSV with average lung scores being normal and no lung 





KS-06 strain had moderate protection as shown by decreased lung scores compared with that in 
unvaccinated-KS-06 challenged pigs (Fig. 2.1C).  
 
In addition, complete protection in vaccinated pigs against homologous challenge was confirmed 
with the absence of PRRS viral RNA in the serum on DPC 7. As shown in Figure 2.1D, pigs 
vaccinated with MLV had efficiently cleared the VR-2332 challenge virus from the blood to 
undetectable levels and vaccinated pigs challenged with the KS-06 strain had less circulating 
PRRSV in the blood than that in unvaccinated-KS-06 challenged pigs, but the difference was not 
statistically significant. By DPC 14, the levels of PRRSV virus circulating in the blood were 
reduced significantly in all vaccinated groups. Therefore, our results suggest that PRRSV MLV 
can protect pigs from homologous challenge and provide moderate protection against 
heterologous PRRSV challenge. 
 
2.3.2 Serum neutralizing antibody titer is associated with PRRSV vaccination-induced 
protection against homologous and heterologous challenge 
It has been suggested that vaccine induced PRRSV-specific antibody production is important for 
inducing protection against subsequent challenges [2,15,16]. To verify that, we analyzed 
PRRSV-specific ELISA antibodies in homologous- and heterologous-challenged pigs using 
commercial IDEXX ELISA kit. Serum samples were collected at various time points and used to 
determine the PRRSV-specific antibody levels. As shown in Figure 2.2A, vaccinated pigs 
produced PRRSV-specific antibodies starting from DPV 14. Interestingly, the antibody titers in 
vaccinated pigs were not further enhanced by PRRSV challenge. Additionally, it was found that 
unvaccinated pigs challenged with the KS-06 isolate showed a faster onset and higher ELISA 
antibody titers than unvaccinated pigs challenged with VR-2332 (Fig. 2.2A).  
 
PRRSV-specific neutralizing antibodies play a critical role in anti-PRRS immunity. A previous 
study showed that passive transfer of neutralizing antibodies with a titer of 8 to recipient piglets 
protected them from challenge-induced viremia, while transfer of serum titers of 32 produced 
sterilizing immunity [15], suggesting that neutralizing antibody titers over 8 can protect pigs 





and influenced by both mutation of PRRSV epitopes and virus virulence. Therefore, we analyzed 
the PRRS virus neutralizing antibody (VN) titers in the serum of different treatment groups. As 
shown in Figure 2.2B, MLV vaccinated pigs began to develop VN titers to VR-2332 at DPV 28 
and the titers were significantly higher at the end of the study as compared with that in 
unvaccinated pigs. It is worth noting that high titer of VN antibodies against the KS-06 stain 
were detected only in pigs vaccinated with MLV but not in unvaccinated pigs after both groups 
of pigs were challenged with the KS-06 strain (Fig. 2.2C). To assay for broad neutralizing 
activity, another PRRSV strain, NVSL97-7895, was used to measure the VN titer of all serum 
samples. As shown in Figure 2.2D, VN antibodies against NVSL97-7895 were developed only in 
vaccinated pigs, and the serum VN titers in vaccinated pigs challenged with the KS-06 strain 
were higher than that in vaccinated pigs challenged with the homologous VR-2332. This 
indicates that prime-boost (vaccination-challenge) with different strains of PRRSV may generate 
antibodies with a broader neutralizing spectrum. 
 
2.3.3. PRRSV-dependent cytokine expression patterns are PRRSV challenge strain 
specific  
Compared with MLV vaccinated pigs challenged with the KS-06 strain, unvaccinated pigs 
displayed significantly higher IFN-α level in the serum (Fig. 2.3A). In contrast, the difference in 
IFN-α production was not detected between vaccinated and unvaccinated pigs after they were 
challenged with VR-2332.  Interestingly, vaccinated pigs produced significant higher levels of 
IL-8 compared with unvaccinated pigs after they were challenged with VR-2332 (Fig. 2.3A).  
TNF-α expression levels were low in all pigs and there was no significant difference among 
treatment groups.  Furthermore, serum IL-10 levels were significantly higher in unvaccinated 
pigs after KS-06 PRRSV challenge than that in vaccinated pigs (Fig. 2.3B). In contrast, 
vaccinated pigs displayed a higher level of serum IL-4 after VR-2332 challenge compared with 
unvaccinated pigs (Fig. 2.3B). There was no significant difference in serum levels of IFN-γ 
among all treatment groups. 
 
Vaccination with PRRS-MLV has been shown to induce the production of IFN-γ-secreting cells 





IFN-γ-secreting cells in PBMCs was evaluated on DPC 14 in a recall response in which PBMCs 
were re-stimulated with VR-2332, KS-06 or NVSL97-7895 PRRSV. As shown in Figure 2.3C, 
when re-stimulated with VR-2332, PBMCs from vaccinated pigs challenged with the KS-06 
strain developed more IFN-γ-secreting cells than that from the other three groups. When re-
stimulated with KS-06 or NVSL97-7895, PBMCs from KS-06 challenged pigs produced 
significantly higher amount of IFN-γ-secreting cells than that from pigs challenged with VR-
2332. Finally, the ratios of IFN-γ-secreting cells in PBMCs re-stimulated with KS-06 PRRSV in 
all treatment groups were significantly lower than that in PBMCs re-stimulated with VR-2332 or 
NVSL97-7895. 
 
 2.3.4. T lymphocyte sub-populations vary between unvaccinated and vaccinated 
groups and are independent of PRRSV challenge strain 
T lymphocyte sub-populations are reported to vary in pigs after challenge with different PRRSV 
strains [18]. In this study, we evaluated the changes in frequency of various lymphocyte 
populations before and after PRRSV challenge in all experimental groups. On DPV 28, the 
frequencies of T-helper cells (Fig. 2.4A), cytotoxic T lymphocytes (CTLs; Fig. 2.4B), and γδ T 
cells (Fig. 2.4D) in PBMCs were similar in vaccinated and unvaccinated pigs, while the 
frequencies of Th/memory cells in unvaccinated pigs were lower compared with that in 
vaccinated pigs (Fig. 2.4C). On DPC 14, the frequencies of T-helper, Th/memory, and γδ T cells 
in PBMCs from vaccinated pigs were higher than that from unvaccinated pigs. It is worth noting 
that the frequencies of various T cell populations in PBMCs from vaccinated or unvaccinated 
pigs were not affected by the difference in challenge strains (VR-2332 vs. KS-06), suggesting 
that PRRSV challenge strain does not affect T cell subpopulations.   
 2.4. Discussion  
As one of the most prevalent diseases in swine, PRRS has caused vast economic losses to the pig 
industry worldwide. Adding to its devastation, the rapid evolution rate of PRRS virus worldwide 
generates countless genetically distinct field isolates, many of which have increased pathogenic 
ability [2,10,18].  Recent outbreaks of PRRSV in China were characterized by high 
morbidity/mortality and commercially available PRRSV vaccines offered no protection [19] 





emerging PPRSV field strains. Therefore, studies on the difference of immune responses to 
homologous and heterologous challenge lay an important foundation for the development of 
effective vaccines and eradiation strategies. The present study evaluated the differences of 
immune responses between vaccinated and unvaccinated pigs when challenged with homologous 
or heterologous PRRSV. We have demonstrated that serum neutralizing antibody titers are 
associated with PRRSV vaccination-induced protection against homologous and heterologous 
challenge. 
  
PRRSV neutralizing activity is associated with antibodies directed against both nonstructural and 
structural proteins including NSP2, GP2, GP4, and GP5. A recent review suggests that the 
variability within GP5 may explain the deficiency in cross-protection of current vaccines against 
heterologous strains of PRRSV [5]. VR-2332 (homologous) and KS-06 strain (heterologous), the 
PRRS viruses used for challenge experiments in this study, share 99.7% or 90.2% similarity with 
the PRRSV-MLV vaccine strain based on GP5 amino acid sequence, respectively. From gross 
lung pathology and viremia results, homologous VR-2332 PRRSV infection was fully prevented 
after vaccination with PRRSV-MLV as evidenced by lack of virus in sera on DPC 7 and normal 
gross lung pathology scores (Fig.2.1C, D). Viremia and gross lung pathology scores in the 
vaccinated pigs challenged with the KS-06 strain were decreased compared with that in the 
unvaccinated pigs, which indicate MLV vaccination can lead to partial protection to 
heterologous PRRSV. These results allow us to compare the immune responses from pigs with 
complete, partial, and no (unvaccinated) protection against PRRSV challenge. 
 
By DPV 14, antibodies specific for N proteins of PRRSV, as measured by the IDEXX ELISA 
kit, were detected in vaccinated pigs and increased throughout the experimental period. PRRSV-
specific antibodies were similar between vaccinated groups throughout the study, suggesting that 
anti-N protein antibodies are not predictive of PRRSV protection. Interestingly, we did observe 
that KS-06 PRRSV challenge induced a faster anti-PRRSV antibody response as compared with 







In contrast to anti-N protein antibodies, virus neutralizing antibodies (VNs) have been shown to 
correlate with protection to PRRSV [15,19]. We found that VNs to different PRRSV strains did 
not start to emerge until DPV 28 in the vaccinated pigs. At the time of PRRSV challenge (DPV 
28), vaccinated pigs developed higher VN titers to VR-2332 (Fig. 2.2B) than to KS-06 strain 
(Fig. 2.2C), suggesting an association between PRRSV strain-specific VN titer and level of 
protection to PRRSV. Vaccinated pigs did not develop VNs to KS-06 after vaccination, but 
developed significantly higher VN titers to KS-06 as compared with the other three groups two 
weeks after challenge, which suggests that the KS-06 specific VN could be induced by KS-06 
challenge (Fig.2.2C). Also, vaccinated and KS-06 challenged pigs developed a higher level of 
VN antibodies to the heterologous NVSL97-7895 PRRSV strain (Fig.2.2D). This result supports 
the notion that two vaccinations with different PRRSV strains can generate higher neutralizing 
Abs and broader cross-protection against various PRRSV field strains.  Similar observation has 
been reported in influenza virus vaccination strategy studies [21].  
 
It was reported that PRRSV can inhibit the expression of IFN-α [22]. However, we found that 
the level of IFN-α was increased in unvaccinated pigs challenged with KS-06 virus.  Similar to 
previous reports, serum level of IFN-α is not associated with the PRRS virus clearance in pigs 
after viral challenges [18]. The serum level of inflammatory cytokine IL-8 in vaccinated pigs 
challenged with homologous VR-2332 virus was the highest among all treatment groups 
(Fig.2.3A).  Our results are consistent with previous  studies which have shown that low level of 
serum IL-8 is seen in persistent PRRSV infection, and elevated IL-8 levels in serum is correlated 
with the clearance of PRRS virus [23]. However, it remains to be determined how elevated IL-8 
may contribute to the clearance of PRRS virus in vaccinated pigs and whether the level of serum 
IL-8 can be used to predict vaccination-induced protection in pigs.  
 
The expression of IL-4 was significantly higher in vaccinated pigs as compared with that in 
unvaccinated pigs after KS-06 challenge. This and our previous study [12] and results from 
others [24]  suggest that increased IL-4 expression may play a positive role in vaccination-
mediated clearance of heterologous PRRS virus.  However, IL-4 level in the serum may not have 
a direct role in protecting pigs from PRRSV infection since pigs challenged with homologous 





important role in the development of vaccination-induced protection against PRRSV has yet to 
be explored in future studies. 
 
PRRSV infection has been shown to induce a strong immunosuppressive response characterized 
by promoting the secretion of IL-10 to antagonize the protective Th1 immune response [25]. In 
our study, we found that IL-10 production in the serum was increased in unvaccinated pigs, but 
not in vaccinated pigs, when they were challenged with the KS-06 strain (Fig.2.3B). In contrast, 
both unvaccinated and vaccinated pigs challenged with VR-2332 had similar levels of serum IL-
10.  The level of serum IL-10 in PRRS infection has been reported to be virus strain-dependent, 
which may be related to the virulence of each viral isolate [25]. Thus, the difference in IL-10 
production between the two challenged groups may be due to the fact that the KS-06 isolate is 
more virulent than the VR-2332 isolate.   
 
IFN-γ is a key cytokine that is associated with host cell-mediated immunity (CMI) response, 
which is secreted by natural killer cells and several different T cell subpopulations. Report has 
shown that the expression level of IFN-γ after PRRSV infection was variable and showed no 
correlation to virus load [26]. In our study, we did not observe any changes to serum levels of 
IFN-γ among the four treatment groups (Fig.2.3B). In a recall response, IFN-γ-secreting cells 
from memory lymphocytes was calculated after removal of the control background data of cells 
which was stimulated with MARC145 cell lysis. MLV vaccination generated higher frequency 
of IFN-γ-secreting cells.  However, PBMCs isolated from vaccinated and KS-06 challenged pigs 
generated more IFN-γ-secreting cells when re-stimulated with homologous or heterologous 
PRRSV as compared with that from unvaccinated pigs (Fig.2.3C). We found that the lowest 
number of IFN-γ-secreting cells was from PBMCs re-stimulated with the KS-06 strain, as 
compared with another heterologous strain NVSL97-7895 or VR-2332 stimulation. This may be 
due to the fact that the KS-06 isolate is more virulent than the other two strains and can cause a 
stronger immunosuppression during infection [18]. Our results suggest that increased IFN-γ 
expression does not correlate with protection against PRRSV as evidenced by lower levels of 
IFN-γ in fully protected vaccinated pigs challenged with VR-2332 compared with partially 
protected vaccinated pigs challenged with KS-06 strain. Therefore, the role of IFN-γ in the 






A high frequency of γδ T cells in pigs is considered to be related to the activation status of the 




 double positive T cells possess memory, T-helper and 
cytolytic properties [27, 28]. Although significant increases in the frequency of T helper, 
Th/memory and γδ T cells in PBMCs were observed in vaccinated pigs compared with that in 
unvaccinated pigs, and this may suggest a protective role of these cells against PRRSV infection, 
this parameter cannot predict the level of protection since changes in T cell subpopulations are 
similar between fully and partially protected groups of pigs.  
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Figure 2.1. Vaccination with PRRSV-MLV induced complete protection to homologous PRRSV 
challenge and partial protection to heterologous challenge. (A) Experimental timeline. (B) Rectal 
temperature of pigs was monitored daily after PRRSV challenge. (C) Gross lung lesion scores 
present in all lung lobes on DPC 14 were scored using a 4 point scale. (D) PRRSV viral RNA in 
the serum was determined by qPCR, a standard curve was used for calculation of TCID50 of viral 









Figure 2.2. Serum neutralizing antibody titer is associated with PRRSV vaccination-induced 
protection against homologous and heterologous challenge. (A) PRRSV-specific antibodies were 
detected in the serum using IDEXX ELISA kit. The threshold for positive sera was set at a 
sample to positive (s/p) ratio of 0.4 according to the manufacturer’s instructions. (B-D) Serum 
samples were titrated on MARC-145 cells and the levels of anti-PRRSV neutralizing Abs were 
determined as the reciprocal of the highest dilution that could inhibit CPE. Data were shown as 







Figure 2.3. PRRSV-dependent cytokine expression patterns are PRRSV challenge strain 
specific. (A) Innate and (B) adaptive cytokine expression profiles in the sera of pigs at DPC 7 
were tested by ELISA. (C) PBMCs collected at DPC 14 were re-stimulated with VR-2332, KS-
06 or NVSL97-7895 strains of PRRSV. IFN-γ-secreting cells were then analyzed by ELISpot 







Figure 2.4. T lymphocyte sub-populations vary between unvaccinated and vaccinated groups 
and are independent of PRRSV challenge strain. PBMCs were isolated from pigs at necropsy 
(DPC 14) and T cell subsets were determined by flow cytometry analysis according to their 
























. Data were shown as mean ± SEM 






Chapter 3 - Montanide
TM
 Gel 01 ST adjuvant enhances PRRS 




Porcine reproductive and respiratory syndrome (PRRS) is a devastating disease caused by the 
PRRS virus. The Montanide
TM
 class of flexible polymeric adjuvants has recently been shown to 
enhance protective immunity against PRRSV infection in piglets when used in combination with 
PRRS modified live vaccines (MLV). In this study, we explored the efficacy and imunological 
mechanisms of protection of Montanide
TM
 Gel 01 ST (Gel01) adjuvanted modified live PRRS 
vaccine in pigs challenged with two genetically distinct strains of PRRSV.  Gel01-MLV reduced 
lymph node pathology scores in pigs challenged with VR-2332 (parental strain of MLV vaccine) 
but not that in pigs challenged with MN184A (heterologous strain), when compared with that in 
pigs vaccinated with un-adjuvanted MLV.  Pigs vaccinated with Gel01-MLV had higher levels 
of PRRS-specific antibodies, as measured by IDEXX ELISA and virus neutralizing antibodies, 
after vaccination and VR-2332 challenge. In addition, pigs vaccinated with Gel01-MLV had 
decreased levels of IFN-γ, IL-10, and T-regulatory lymphocytes in the blood as compared with 
that in pigs vaccinated with MLV alone. Interestingly, we found that addition of Gel 01 ST did 
not change the profile of other T lymphocyte populations after PRRSV challenge. These results 
demonstrate that the MLV adjuvanted with Gel01 provides enhanced protection against 
homologous PRRSV infection, possibly by regulating the production of PRRSV-specific 
antibodies and cytokines involved in the development of T-regulatory cells. Thus, Gel 01 ST is a 
promising adjuvant that can be formulated with PRRSV MLV vaccines to reduce disease 
severity and tissue damage caused by PRRSV infection in pigs.  
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 Gel 01 ST adjuvant enhances PRRS 
modified live vaccine efficacy by regulating porcine humoral and cellular immune responses. 





 3.1. Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is currently one of most devastating 
swine diseases worldwide, causing immense economic losses in the swine industry [1]. It was 
estimated that the US pork industry alone has annual losses of $664 million due to the prevalence 
of PRRS [2]. The causative agent, PRRS virus (PRRSV), belongs to the family Arteriviridae, 
order Nidovirales, and causes reproductive failure in sows including still births, mummification, 
week-born piglets and high pre-weaning mortality [3]. Currently, commercially available PRRS 
modified live vaccines (MLVs) are widely being used in the US to control PRRSV infection [4]. 
However, the efficacy of these MLVs is debated due to limited protection against antigenically 
diverse heterologous PRRS virus isolates [5].  
 
Current formulations of MLV do not contain adjuvants since the multiplication and infectious 
properties of attenuated live PRRS virus have been shown to induce sufficient protection to 
PRRSV infection [6]. However, due to the high degree of genetic variation of PRRSV, new 
strains are quickly emerging that current vaccine formulations may not be able to protect against. 
Recently, several studies showed that addition of adjuvants, such as Mycobacterium tuberculosis 
whole cell lysate, to PRRS modified live vaccine (PRRS-MLV) can induce enhanced cross-
protective immunity to PRRSV [7].  However, the addition of these experimental adjuvants to 
commercially available vaccines still requires large-scale trials and certification by USDA before 
they can be brought to market. By contrast, the Montanide
TM
 class of adjuvants is a well-
established brand of vaccine adjuvants, which are already approved in Europe and included in 
several registered commercial veterinary vaccines for food animals including cattle, poultry, and 
fish. These Montanide
TM
 adjuvants have been shown to enhance disease protection when 
combined with diverse types of antigens [8]. Recently, one research group used Montanide
TM
 
Gel 01, a polymer based adjuvant, to adjuvant PRRS attenuated live vaccine and found the 
addition of Gel 01 enhanced protection from PRRS in vaccinated animals, even in formulations 
containing half the dose of the modified live PPRSV [9].  However, they did not evaluate the 
cross-protection potential of the Gel01 adjuvant or mechanism of increased protection. 
Therefore, using Gel 01 ST as an adjuvant, we evaluated PRRS MLV-induced humoral and 





whether Gel01-adjuvanted PRRS MLV can provide broader cross-protection to field strains of 
PRRSV.  
 
 3.2. Materials and Methods 
 3.2.1. Cells, virus and adjuvant preparation 
Marc-145 cells were maintained in Modified Eagle’s medium (MEM) supplemented with 7% 
fetal bovine serum (FBS) containing 100U penicillin/ml and 100ug streptomycin/ml at 37°C 
with 5% CO2. Virus stocks were prepared and titrated in Marc-145 cells and stored in aliquots in 
-80°C until use. For virus infection and titration, MEM supplemented with 2% FBS was used. 
Modified live virus vaccine (PRRS-MLV) was purchased from Boehringer Ingelheim Vetmedica 
Inc. PRRSV VR-2332, the parental strains of MLV, was purchased from ATCC. PRRSV 
MN184a was a kind gift from Dr. Kay Faabberg in United States Department of Agriculture. 
Montanide
TM
 Gel 01 ST (Gel01) polymeric adjuvant was a kind gift from Dr. Robert Parker 
(SEPPIC Inc.).  A final 10% of Gel 01 was added into diluted PRRS modified live vaccine and 
mixed by manual shaking. 
 3.2.2. Pigs, vaccination and challenge 
Thirty-five conventional Large White-Duroc crossbred weaned specific-pathogen free piglets at 
3 weeks of age were housed at the Large Animal Research Center (LARC) facility, within 
Kansas State University. These piglets were confirmed sera-negative for antibodies to PRRSV 
by ELISA and PRPSV-free in the blood by RT-PCR. Pigs were allowed to acclimate for an 
additional week before initiation of the experiment. Pigs were immunized intramuscularly on day 
post-vaccination (DPV) 0 with MEM (placebo) or vaccine (PRRS-MLV, 1x10
6
 TCID50/ pig) 
formulated with or without 10% Gel 01 adjuvant. After four weeks, the pigs were challenged 
with either homologous PRRSV VR-2332 (1×10
6
 TCID50) or heterologous PRRSV MN184a 
(5×10
5
 TCID50)   Pigs were monitored for body weight once a week and clinical signs of 






 3.2.3. Collection of blood samples for analysis 
 
Blood was collected on DPV 0, 7, 14, 21, 28, DPC 7 and 14. Serum was separated from clotted 
blood and preserved at -20°C until used in assays. Serum was used for evaluation of viremia, 
viral titer, serum neutralizing antibody titers, and ELISA antibody titer (HerdCheck Porcine 
Reproductive and Respiratory Syndrome Antibody test Kit, IDEXX Laboratories) to PRRSV as 
previously described. Peripheral blood mononuclear cells (PBMCs) were isolated from a 
heparinized blood sample by Ficoll-Hypaque gradient centrifugation using Histopaque®-1077 
(Sigma-Aldrich, St. Louis, MO). PBMCs were used for ELISpot assay, flow cytometry and real-
time PCR analysis. 
 
 3.2.4. Gross lung and lymph node lesion analysis 
 
Pigs were humanely euthanized on DPC 14 as approved by Kansas State University Institutional 
Animal Use and Biosafety Committees. To evaluate lung and lymph node histopathology, slices 
of lung tissue from each lobe and lymph nodes were formalin-fixed, paraffin embedded, 
sectioned and stained with hematoxylin and eosin (H&E). Scoring of macroscopic and 
microscopic lung/lymph node pathology was done in a blinded fashion by two veterinary 
pathologists in the Kansas State Veterinary Diagnostic Laboratory (KSVDL). 
 
 3.2.5. Virus neutralizing antibody titration 
 
Serum samples were heat inactivated (56°C, 30min) and serially diluted before the titration. The 
serial dilutions of serum were mixed with equal volumes of PRRSV VR-2332 or MN184a, 
respectively, containing 200 TCID50 viruses. After incubation at 37°C for 1h, the mixtures were 
transferred to Marc-145 monolayers in 96-well plates. After incubation for 72h at 37°C in a 
humidified atmosphere containing 5% CO2, cells were examined for cytopathic effects (CPE). 
CPE was used to determine the end-point titers that were calculated as the reciprocal of the 






 3.2.6. ELISpot assay 
 
Briefly, 5 x 10
5
 PBMCs were plated in enriched RPMI in a 96-well multiscreen plate (Millipore, 
Billerica, MA) pre-coated overnight with capture IFN-γ mAB (BD pharMingen, San Diego, CA). 
PBMCs were re-stimulated with three different strains of PRRSV at 0.1 MOI for 24h at 37°C. 
IFN-γ-secreting cells were detected by biotinylated anti-pig IFN-γ detection antibody and 
visualized using the immunospot image analyzer (Cellular Technology,Cleveland, OH). Data 
were presented as the mean number of antigen-specific IFN-γ-secreting cells per 10
6
 PBMCs 
from duplicate wells of each sample. 
 
 3.2.7. Flow cytometry analysis 
Flow cytometry analysis was performed to determine different lymphocyte populations based on 






























). Mouse anti-pig TcR1N4 antibody was purchased from VMRD 
(Pullman, WA), and the rest antibodies used in this study were purchased from BD Biosciences. 
Immuno-stained cells were acquired using a FACS Caliber (BD Biosciences) flow cytometer. 
Frequencies of individual lymphocyte were analyzed by 100,000 events using FlowJo software 
(Tree Star, Inc., OR, USA). 
 
 3.2.8. Analysis of serum PRRS virus titer  
 
Total RNA was extracted from 100ul serum using TRIzol® Reagent. One-step SyBR Green real-
time PCR (Bio-Rad) was performed to evaluate PRRSV ORF7 expression level as previously 
described [10]. For quantification, total RNA of known TCID50 of virus were 10-fold serially 
diluted and were used to generate standard curve. Virus quantity of unknown samples was 
determined by linear extrapolation of the Ct value plotted against the standard curve. 
 






Pig sera collected at necropsy and culture supernatants harvested after in vitro restimulation of 
one million of PBMC, TBLN, and lung MNC were analyzed by ELISA kit (Invitrogen, CA) for 
secretion of IL-10 cytokine.  
  
 3.2.10. Statistical analysis 
 
All data were expressed as the mean value of five pigs ± SEM. The differences among each 
group were determined by the paired t test (Prism5.0, GraphPad Software, SanDiego, CA). 
Differences were considered statistically significant when P<0.05. 
 
 3.3. Results 
3.3.1. Addition of Montanide
TM
 Gel 01 ST adjuvant to MLV provided enhanced 
protection against homologous VR-2332 challenge but not heterologous MN184a 
PRRSV challenge in pigs 
Currently, the most effective vaccines for PRRS, including MLV, are cell-culture attenuated 
strains of PRRSV. However, the high incidence of genetic mutation during PRRSV transmission 
often results in vaccines based on strains of PRRSV isolated twenty years ago, such as MLV, 
having limited protection to new emerging viral strains. Therefore, there is a growing need to 
develop new vaccines or significantly improve the ones currently available. Previous studies 
have shown that the Montanide
TM
 line of adjuvants may be able to improve the protection 
potential of commercially available PRRSV MLV to emerging field isolates of PRRSV [9]. To 
determine the cross-protection potential of Gel 01, pigs were mock vaccinated or vaccinated with 
modified live PRRSV vaccine formulated with or without Gel 01 adjuvant. Twenty eight days 
after vaccination, pigs were challenged with homologous VR-2332 (isolated in 1992) or 
heterologous MN184a (isolated in 2002) strains of PRRSV. Gel01 was tested to be safe when 
combined with MLV in our vaccination protocol. We did not observe injection site reactions in 
any group (data not shown) and pigs vaccinated with MLV adjuvanted with Gel01 had 
equivalent net body weight gain compared with control challenged pigs (Fig.3.1A). Clinically, 





challenge. The mean body temperature of unvaccinated pigs challenged with VR-2332 or 
MN184a was 0.3 or 1.0 
o
C higher, respectively, compared with vaccinated pigs with no 
differences between MLV and Gel01-MLV groups (data not shown).  
 
At necropsy, 14 days post challenge (DPC), Gel01-MLV vaccinated pigs had slightly lower lung 
lesion scores, although not statistically significant, compared with MLV vaccinated pigs 
challenged with VR-2332 (Fig.3.1B). However, lymph node pathology scores were significantly 
lower in Gel01-MLV pigs than MLV vaccinated pigs with homologous VR-2332 challenge 
(Fig.3.1C). Interestingly, Gel01 adjuvant addition was unable to reduce MN184a-induced lung 
lesion and lymph node pathology scores. Protection from disease in vaccinated pigs with or 
without Gel01 was also associated with a significantly reduced PRRS virus titer at DPC14 
(Fig.3.1D). Circulating VR-2332 PRRSV was cleared in the blood by DPC14 in both MLV and 
Gel01-MLV vaccinated groups, and a reduced MN184a PRRSV titer in the blood was observed 
in both vaccinated groups. However, there was no difference between Gel01-MLV and MLV 
vaccinated groups for the level of viremia (Fig.3.1D). Taken together, our results suggest that 
addition of Gel01 to MLV can enhance protection of homologous but not heterologous PRRSV 
infection in pigs. 
 
3.3.2. Pigs vaccinated with Gel01 adjuvanted MLV have enhanced PRRSV-specific 
antibodies and virus neutralizing antibodies after homologous PRRSV challenge 
Since pigs vaccinated with Gel01-adjuvanted MLV demonstrated enhanced protection against 
homologous PRRSV challenge, we next wanted to explore the immunological mechanisms of 
improved vaccination efficacy. The presence of vaccine-induced PRRSV-specific antibodies has 
been shown to correlate with the protection against disease [11]. Therefore, serum samples were 
analyzed for PRRSV specific ELISA antibodies and neutralizing antibodies before and after 
PRRSV challenge. Pigs vaccinated with Gel01-MLV developed significantly higher IDEXX 
ELISA antibody titers (indicated by value of S/P) on 21 DPV than the MLV vaccinated or 
unvaccinated pigs (Fig.3.2A and 3.2B). After challenge, the ELISA antibody titers were only 
significantly higher in Gel01-MLV vaccinated pigs than that in MLV vaccinated pigs when 






The presence of VR-2332 and MN184a PRRSV strain-specific neutralizing antibodies were also 
assayed in the serum of all groups of pig at 14 DPC.  Neutralizing antibody titers to VR-2332 
were higher in Gel01-MLV pigs than that in MLV vaccinated pigs when challenged with VR-
2332 (Fig.3.2C). But there was no difference in neutralizing antibody titers to MN184a between 
these two vaccinated groups when pigs were challenged with VR-2332 or MN184a. Therefore, 
our results suggest that Gel01 adjuvant may be facilitating the production of PRRSV-specific 
antibodies, including neutralizing antibodies, leading to enhanced protection against VR-2332 
challenge. 
 
3.3.3. Pigs vaccinated with Gel01 adjuvanted MLV have decreased PRRSV-specific 
IFNγ and IL-10 cytokines after PRRVS challenge.  
Our results thus far show that the addition of Gel01 adjuvant to the MLV PRRSV vaccine acts to 
increase the humoral immune response in pigs challenged with homologous PRRSV. In addition 
to antibody responses, cytokines expression profiles and cell-based immune responses are 
involved in the resolution of PRRSV infections [12]. In order to determine whether cellular 
immune responses were also enhanced by Gel01 adjuvant, PBMCs were isolated from blood 
samples in each group at 14 DPC.  We found that the Gel01-MLV group of pigs challenged with 
VR-2332, as compared with MLV group, developed a lower frequency of IFN-γ-secreting cells 
when re-stimulated with the homologous virus (Fig.3.3A). Additionally, the secretion of 
immunosuppressive cytokine IL-10 by PBMCs was also reduced in the Gel01-MLV vaccinated 
pigs, but not in MLV pigs, challenged with VR-2332 or MN184a (Fig.3.3B). To further confirm 
the decreased IL-10 cytokine expression induced by the addition of the Gel01 adjuvant, serum 
IL-10 and IL-10 secreted by lung MNCs were also analyzed. As shown in figure 3.3C and D, 
reduced IL-10 cytokine secretion was also found in the serum, but not in the supernatant of lung 
MNC, of the Gel01-MLV vaccinated pigs challenged with homologous VR-2332 but not 
heterologous MN184a virus. Therefore, these results suggest that Gel01 adjuvant may increase 
MLV-mediated protection against homologous PRRSV infection using a mechanism that 






3.3.4. Pigs vaccinated with Gel01 adjuvanted MLV had reduced T-regulatory cell 
populations after PRRSV challenge 
Finally, since the immune response and cytokine expression patterns are modulated by different 
T cell sub-populations, the phenotype and frequency of various lymphoid immune cells in pigs 
were also analyzed by flow cytometry. The frequency of different immune cells at 14 DPC are 
shown in table 3.1.  Interestingly, we found a significant decrease of the T-regulatory cell 
population in TBLNs and lung MNCs in Gel01-MLV vaccinated pigs compared with the MLV 
vaccinated pigs after both VR-2332 and MN184a challenge (Fig.3.4A and B).  We did not 
observe any significant differences among total T cell population, T-helper cells, cytotoxic T 
cells, Th/memory cells, or γδ T cells (Table3.1). Taken together, our results suggest that, when 
combined with PRRSV MLV, Gel01 adjuvant can enhance the protection against homologous 
PRRSV infection by regulating the development of T regulatory cells. 
  
 3.4. Discussion  
Modified live vaccines are widely used in veterinary medicine, as well as in human medicine, to 
control many infectious diseases in a wide variety of hosts [13]. Currently, almost all 
commercially available PRRSV vaccines are modified live vaccines based on cell culture-
attenuated strains of PRRS virus. In general, MLV provides decent protection against 
homologous virus infection; however the antigenic disparity of rapidly emerging field isolates 
leads to partial protection against heterologous viruses [1]. Furthermore, newly emerging isolates 
are more virulent then parental strains and more prevalent in swine farms across the world, 
leading to devastating economic losses [2]. Thus, there is a growing need to improve the current 
PRRS vaccination practices in swine farms.  
 
The efficacy of current PRRS modified live vaccines could be enhanced with the addition of 
adjuvants. In fact, a recent study demonstrated that the addition of adjuvant to MLV led to 
broadened cross-protection to PRRSV field isolates and reduced lung and lymph organ damage 
[7], suggesting that adjuvant addition to MLV would be an effective way to reduce PRRS 





study and it will be too expensive for food animal vaccine markets. On the other hand, a more 
cost-effective commercially available Gel01 adjuvant is proven to be easy to use and stable in a 
variety of veterinary vaccines. The addition of Gel01 adjuvant to PRRS MLV has been reported 
previously [9]. It was reported that Gel01 adjuvant can improve the efficacy of PRRS MLV even 
with half of the antigen load. Gel01-adjuvanted PRRS MLV can reduce viremia after challenge 
and generate equivalent ELISA antibody titers as MLV alone. A better protection was shown by 
the reduced duration of hyperthermia and lung pathological score with administration of Gel01-
adjuvanted PRRS MLV after viral challenge.  
 
Our study shows similar results in that Gel-MLV was able to better protect pigs challenged with 
VR-2332 than pigs vaccinated with MLV alone. However, when pigs were challenged with a 
heterologous strain of PRRSV (MN184a), addition of Gel01 adjuvants did not enhance 
protection (Figure 3.1). The amino acid similarity of structural proteins between MLV and VR-
2332 is more than 99.2%, yet MN184a share only 89.4%, which may have contributed to lack of 
cross-protection after MN184a challenge. Therefore, Gel01 may not be an ideal adjuvant for all 
strains of PRRSV, but rather is strain-specific in the ability to enhance the protective properties 
of MLV.  
 
In our study, pigs vaccinated with Gel0-MLV developed higher titers of PRRSV-specific 
antibodies after vaccination and VR-2332 challenge, as measured by IDEXX ELISA (Fig.3.2A 
and B). However, these ELISA antibodies are non-neutralizing antibodies that are mainly 
directed towards the nucleocapsid (N) protein, and did not provide animals with any protection 
against PRRSV infection [14]. In contrast, PRRSV structural proteins are reported to induce 
protective neutralizing antibody (NA) and PRRSV-specific cellular immune response after 
PPRSV infection [15]. To further evaluate the immunological mechanisms of Gel01-mediated 
adjuvanticity, we found that pigs vaccinated with Gel01-adjuvanted MLV, as opposed to MLV 
alone, generated higher NA titer when challenged with VR-2332 (Fig.3.2C). Interestingly,  pigs 
vaccinated with Gel01-MLV showed higher NA titer to both VR-2332 and MN184a than that in 
pigs vaccinated with MLV alone after they were challenged with PRRSV MN184a . Similar 
results have also been observed on other recently isolated field strains of PRRSV. These results 





heterologous PRRSV strain (challenge-MN184a) are able to generate higher NA titers, a concept 
which has already been shown to occur in influenza virus vaccination [16].  
 
There are several immunomodulatory cytokines that are believed to be responsible for the 
clearance of PRRS virus. Specifically, vaccine-mediated up-regulation of pro-inflammatory 
cytokine IFN-γ has been suggested to be important in the combat against PRRSV infection [17]. 
Interestingly, in our study, pigs receiving Gel01 adjuvanted MLV were better protected against 
homologous PRRSV infected than MLV vaccinated pigs; however, Gel01-MLV pigs had 
decreased IFN-γ (Figure 3.3A). These results suggest that IFN-γ maybe be playing a negative 
role in protecting pigs from disease and agents that can reduce IFN-γ levels in vaccinated pigs 
and may lead to better protection. Additionally, pigs vaccinated with the MLV alone had 
increased IL-10 production as compared with unvaccinated animals and the addition of Gel acted 
to decrease IL-10 to levels to at or below unvaccinated animals (Figure 3.3B and C). During 
PRRSV infection, a significant correlation has previously been observed between the inability to 
effectively protect against disease and the increased expression of cytokine IL10. This could be 
in part due to IL10-mediated reduction of IFN-α, IFN-γ, IL-12 and TNF-α expression, cytokines 
involved in dampening the cellular immune response [5].  Therefore, our results suggest that 
Gel01 adjuvant may act to enhance the protective properties of MLV by decreasing IL-10 
production.  
 
The expression of IL-10 is mainly regulated by T-regulatory cells, which consist of a small 
subpopulation of T lymphocytes [18]. Consistent with IL-10 expression, we found that the 
frequency of T regulatory cells in Gel01-adjuvanted vaccinated pigs was dramatically reduced in 
the TBLNs and lung MNCs (Figure 3.4). Therefore the reduced T-regulatory cell population 
could have contributed to the decreased expression of IL-10 in pigs after vaccination with Gel01-
MLV and challenge with PRRSV. 
 
In summary, our results show that addition of Gel01 adjuvant to PRRSV modified live vaccine 
can confer increased protection to homologous but not heterologous PRRSV challenge, 





IL-10 cytokine production. Therefore, the commercially available Gel01 adjuvant may be a 
useful tool in improving the efficacy of live PRRS vaccines. 
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Figure 3.1. Addition of Montanide
TM
 Gel 01 ST adjuvant to MLV provided enhanced protection 
against homologous VR-2332 challenge but not heterologous MN184a PRRSV challenge in pigs 
(a) The body weight of pigs was monitored weekly for 6 weeks starting on the day of vaccination 
(DPV 0) and concluding 14 days post PRRSV challenge (14 DPC). Fold body weight gain of 
each individual pig was calculated by normalizing the weight of the pig on DPV 0 to 1. (b) Lung 
tissue harvested on 14 DPC was sectioned, stained with H&E, examined, and given an estimated 
score of 0 to 4 based on the severity interstitial pneumonia. (c) Lymph node sections harvested 
on 14 DPC were examined and given a score from 1 to 3 according to the amount of hyperplasia. 
(d) PRRS-specific viral RNA in serum was detected by real-time PCR on 14 DPC. Data are 







Figure 3.2. Pigs vaccinated with Gel 01 ST adjuvanted MLV have enhanced PRRSV-specific 
antibodies and virus neutralizing antibodies after homologous PRRSV challenge (a,b) PRRSV-
specific IDEXX ELISA S/P ratio in each group after vaccination and challenge. The ELISA 
threshold for positive sera was set at a sample to positive (s/p) ratio of 0.4 according 
manufacturer’s instructions. (c) Individual serum samples collected on 14 DPC were titrated in 
Marc145 cells. Anti-PRRSV neutralizing Ab titers were determined as the highest serum dilution 
that could inhibit CPE. Data are shown as mean ± SEM for five pigs per group. An asterisk 






Figure 3.3. Pigs vaccinated with Gel 01 ST adjuvanted MLV have decreased PRRSV-specific 
IFN-γ and IL-10 cytokines after PRRVS challenge. (a) PBMCs collected from pigs at 14 DPC 
were re-stimulated with VR-2332 or MN184a for 24 hrs. IFN-γ-secreting cells were then 
analyzed by the ELISpot assay. (b-d) Blood samples were collected from pigs at 14 DPC. Serum 
and PBMC supernatants were then subjected to ELISA analysis for IL-10 secretion. Lung MNCs 
were also collected at necropsy (14 DPC), re-stimulated with PRRSV, and subjected to IL-10 
detection by ELISA. Data are shown as mean ± SEM for five pigs per group. An asterisk denotes 







 Figure 3.4. Pigs vaccinated with Gel 01 ST adjuvanted MLV had reduced T-regulatory cell 
populations after PRRSV challenge. (a,b) TBLN cells and lung MNCs were isolated from pigs at 
necropsy (14 DPC). Total cell population was gated as CD4
+
 cells, T-regulatory cells were 




 expression. Each bar is an average percent of T-regulatory 






















Table 3.1. Frequency of T cell subpopulations in pigs after challenge with PRRSV 
 
Table 3.1. PBMCs were isolated from blood collected from pigs at necropsy (14 DPC), and T 
cell subsets were counted by flow cytometry according to their phenotypes. Each number is 
expressed as the average percent of total PBMCs from five pigs ± SEM. An asterisk indicates a 








Chapter 4 - Peptide nanofiber hydrogel adjuvanted live virus 
vaccine enhances cross-protective immunity to porcine reproductive 
and respiratory syndrome virus
 3
 
Abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) is prevalent in swine 
farms worldwide and is a major source of economic loss and animal suffering. Rapid genetic 
variation of PRRSV makes it difficult for current vaccines to confer protection against newly 
emerging strains. We recently demonstrated that a novel peptide nanofiber hydrogel (H9e) could 
act as a potent adjuvant for killed H1N1 vaccines. Therefore, the objective of this study was to 
evaluate H9e as an adjuvant for PRRSV modified live virus (MLV) vaccines. Pigs were 
vaccinated with Ingelvac PRRSV MLV with or without H9e adjuvant before being challenged 
with the VR-2332 (parental vaccine strain) or MN184A (genetically diverse strain) PRRSV. Pigs 
vaccinated with MLV+H9e had higher levels of circulating vaccine virus. More importantly, pigs 
vaccinated with MLV+H9e had improved protection against challenge by both PRRSV strains, 
as demonstrated by reduced challenge-induced viremia compared with pigs vaccinated with 
MLV alone.  Pigs vaccinated with MLV+H9e had lower frequency of T-regulatory cells and IL-
10 production but higher frequency of Th/memory cells and IFN-γ secretion than that in pigs 
vaccinated with MLV alone. Taken together, our studies suggest that the peptide nanofiber 
hydrogel H9e, when combined with the PRRSV MLV vaccine, can enhance vaccine efficacy 
against two different PRRSV strains by modulating both host humoral and cellular immune 
responses. 
 
 4.1. Introduction 
Pork is one of the most widely consumed meats in the world, accounting for more than a third of 
meat production worldwide.  Infectious diseases remain the biggest threat to the pork industry, 
resulting in billions of dollars in economic losses [1]. One particularly devastating disease known 
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to lead to the dramatic decline of swine herds and increased pork prices is porcine reproductive 
and respiratory syndrome (PRRS) [1]. Clinical features of PRRS include massive abortion in 
sows and weight loss, respiratory disease, and mortality in young pigs. PRRS outbreaks continue 
to emerge rapidly and with increased virulence; if left untreated, outbreaks will endanger swine 
industries worldwide. 
 
PRRS is caused by the PRRS virus (PRRSV). Field isolates often differ significantly in the 
degree of virulence and pathogenicity, presumably due to a high degree of genetic variation 
among strains [2]. PRRSV can be broadly divided into two distinct genotypes, Type 1 
(European) and Type 2 (North American). Each genotype also contains several subtypes, which 
are also genetically diverse and lead to immunity limited to the initial infecting genotype, with 
only partial or no protection from reinfection by other subtypes [3]. Due to genetic diversity and 
the rapid evolution rate of PRRSV, development of a broadly protective PRRSV vaccine is 
challenging, but vaccination remains the most effective way to control PRRS. Several types of 
commercial vaccines, including killed or modified live vaccines, have been widely used [4]. 
Current killed vaccines are largely ineffective in preventing both PRRSV infection and disease, 
so most farms vaccinate their herds with modified live vaccines to control PRRS outbreaks.  
Modified live vaccines are shown to reduce disease caused by genetically similar strains, but 
they provide very limited or no protection against genetically unrelated field isolates [5]. 
Therefore, broad cross-protection against genetically dissimilar PRRSV strains should be the 
main consideration for the design of improved PRRSV vaccines.   
 
Adjuvants including oil-in-water emulsions, polymers, and bacterial antigens have been tested in 
combination with modified live vaccines in an effort to reduce the antigenic load and improve 
vaccine efficacy [6,7]. Results from these studies suggest that addition of adjuvant to MLV 
PRRSV vaccines can lead to increased protection to PRRSV challenge. Peptide hydrogels also 
might be a promising delivery system for vaccines due to their high water content, polymer 
network and reversible sol-gel (solution to gel) formation. Peptide hydrogels have been well 
studied as drug delivery systems, for tissue engineering applications, and in 3-D cell culture and 
show promising results [8,9]. We recently developed a novel peptide that can form a flexible 





[10]. To further characterize the capabilities of the H9e hydrogel, we evaluated H9e as an 
adjuvant for PRRSV MLV vaccines. Results show that the addition of H9e to MLV enhanced 
protection of pigs to both homologous and heterologous strains of PRRSV. Compared with pigs 
vaccinated with MLV alone, animals vaccinated with MLV+H9e developed earlier and more 
robust PRRSV-specific neutralizing antibodies as well as increased PRRSV-specific Th1 
cytokine IFN-γ and reduced immunosuppressive cytokine IL-10. Together, these results suggest 
that PRRS MLV vaccine formulated with H9e adjuvant may increase vaccine efficacy against 
genetically diverse PRRS viruses. 
 
 4.2. Materials and Methods 
4. 2.1. Cells, virus and adjuvant preparation 
MARC-145 cells were maintained in modified Eagle’s medium (MEM) supplemented with 7% 
fetal bovine serum (FBS) containing penicillin (100U/ml) and streptomycin (100 µg/ml) at 37 °C 
with 5% CO2. For virus infection and titration, MEM supplemented with 2% FBS was used. 
Ingelvac PRRS
®
 modified live virus vaccine (MLV) was purchased from Boehringer Ingelheim 
Vetmedica Inc (St. Joseph, MO). PRRSV MN184A was a kind gift from Dr. Kay Faaberg 
(National Animal Disease Center, USDA-ARS, Ames, IA). PRRSV strains VR-2332 (ATCC, 
Manassas, VA) and MN184A were prepared and titered in MARC-145 cells and stored in 
aliquots at -80 °C until use. H9e peptide was prepared as previously described with a final 
concentration of 17.5 mg/ml [10]. PRRS MLV vaccine was resuspended in 50 ml vaccine 
diluent, provided by the manufacturer, to yield a 2-fold concentrate of vaccine virus. MLV-alone 
vaccine was then mixed 1:1 with vaccine diluent. A solution of 6 mg H9e with 1.2% porcine 
serum in diluent/MEM medium was added 1:1 with 2x MLV to prepare MLV+H9e vaccine. 
 
4.2.2. Pigs, vaccination and PRRSV challenge 
Thirty-five female/unvaccinated (3 weeks old) Large White-Duroc crossbred PRRSV-free pigs 
were divided into 7 groups (n = 5) and housed in separate pens within the Large Animal 
Research Center (LARC) at Kansas State University. These piglets were confirmed sera-negative 





immunized intramuscularly on day 0 with placebo, PRRS-MLV (1x10
6 
TCID50/ pig), or PRRS-
MLV+H9e (1x10
6 
TCID50 + 6 mg H9e/ pig). Twenty-eight days post vaccination (DPV), the pigs 
were challenged with either homologous PRRSV VR-2332 (1x10
6 
TCID50) or heterologous 
MN184A (5x10
5 
TCID50). Body weight measurements and blood samples were collected weekly 
(0, 7, 14, 21, 28 DPV and 7, 14 DPC). Pigs were also monitored daily for rectal temperature and 
clinical signs after challenge. All pigs were humanly euthanized 15 days post challenge (DPC). 
All animal experiments were approved by the Institutional Animal Care and Use Committee at 
Kansas State University. 
 
4.2.3. Analysis of serum virus titer 
Total RNA was extracted from serum and one-step SyBR Green real-time PCR (Bio-Rad, 
Hercules, CA) was performed to evaluate the PRRSV ORF7 expression level as previously 
described [11]. For quantification, total RNA of a known TCID50 of virus was 10-fold serially 
diluted and were used to generate a standard curve. The virus quantities of unknown samples 
were determined by linear extrapolation of the Ct value plotted against the standard curve. 
 
4.2.4. PRRSV-specific and virus neutralizing antibody titration 
PRRSV-specific ELISA antibody titers were measured using the Herdcheck Porcine 
Reproductive and Respiratory Syndrome X3 Antibody Test (IDEXX Laboratories, Westbrook, 
ME) as described by the manufacturer. Virus neutralizing antibody titer in the serum was 
analyzed as previously described [11]. Briefly, serum samples were heat-inactivated and serial 
dilutions were mixed with PRRSV VR-2332 or MN184A viruses. After incubation, the mixtures 
were transferred to MARC-145 cells and incubated for 72 hours. Cytopathic effect (CPE) was 
used to determine the end-point titers that were calculated as the reciprocal of the highest serum 







4.2.5. Analysis of cytokine responses 
Pig sera were collected at 7 DPC to evaluate IL-4, IL-8, IL-10, IFN-γ, and TNF-α cytokine 
secretion profiles by ELISA. Procedures were performed as per the manufacturer’s instructions 
(Invitrogen, Carlsbad, CA). Additionally, at necropsy (15 DPC), 10
6
 tracheobronchial lymph 
node (TBLN) mononuclear cells (MNCs) and lung MNCs were restimulated with 200 TCID50 of 
the respective challenge PRRSV similar to that described in Ferrari et al. [12]. Cell culture 
supernatants were analyzed by ELISA for IL-10 cytokine secretion (Invitrogen). 
 
4.2.6. Flow cytometry analysis 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood samples by 
Ficoll-Hypaque gradient centrifugation using Histopaque
®
-1077 (Sigma-Aldrich, St. Louis, 
MO). Flow cytometry analysis was performed to determine different lymphocyte populations 






























). The mouse anti-pig TcR1N4 antibody 
was purchased from VMRD (Pullman, WA), and all other antibodies were purchased from BD 
Biosciences (San Jose, CA). Immuno-stained cells were acquired using a FACS Caliber (BD 
Biosciences) flow cytometer. Frequencies of individual lymphocytes were analyzed by 100,000 
events using FlowJo software (Tree Star, Inc., Ashland, OR). 
4.2.7. Statistical analysis 
All data were expressed as the mean value of five pigs ± SEM. The differences in the level of 
humoral response, body weight, cytokine production and viremia among each group were 
determined by the one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s test 
using Sigmaplot 11 software (Systat Software Inc., San Jose, CA). Differences were considered 







4.3.1. H9e adjuvant enhances cross-protection efficacy of MLV to heterologous 
PRRSV infection in pigs 
Our previous studies showed that H9e hydrogel can be a safe, efficacious adjuvant for the killed 
H1N1 swine influenza vaccines, resulting in significantly higher hemagglutination inhibition 
titers and antibody titers to swine influenza than immunization with antigen alone [10]. Since 
H9e acts as a potent adjuvant for killed subunit vaccines, we hypothesized that H9e hydrogels 
could also work as an adjuvant for a modified live PRRS vaccine. 
 
H9e solution is a free-flowing solution at ambient temperature, and forms an injectable hydrogel 
at physiological conditions. H9e was easily mixed with MLV and showed no virucidal effects on 
the vaccine virus (data not shown). Pigs were vaccinated with Ingelvac PRRS MLV vaccine 
alone (MLV), Ingelvac PRRS MLV vaccine adjuvanted with hydrogel H9e (MLV+H9e), or PBS 
(mock). Twenty-eight days post vaccination (DPV), pigs were subjected to virus challenge with 
low virulence homologous VR-2332 (1 x 10
6
 TCID50/pig) or moderately virulent heterologous 
MN184A (5 x 10
5
 TCID50/pig) strains of PRRSV. The mean body temperature of unvaccinated 
pigs challenged with VR-2332 or MN184A was 0.3 or 1.0
o
C higher than vaccinated pigs, 
respectively, with no difference between vaccinated groups (data not shown). Interestingly, pigs 
vaccinated with MLV gained significantly less weight than unvaccinated and MLV+H9e 
vaccinated pigs at 28 DPV (Fig. 4.1A, B), suggesting that the un-adjuvanted MLV vaccine virus 
may cause sub-clinical disease in pigs.  
 
To determine if vaccinated pigs were protected from homologous or heterologous virus 
challenge, titers of circulating virus were measured 7 days post challenge (DPC). We found that 
the pigs vaccinated with MLV+H9e were able to significantly clear both the VR-2332 and 
MN184A strains circulating in the blood 7 days post challenge (7 DPC). Pigs vaccinated with 
MLV alone were able to significantly clear the homologous VR-2332 virus strain (Fig.4.1C). 
The pigs vaccinated with MLV alone had reduced viral load in the blood after MN184A 





group of pigs (Fig. 4.1D). Taken together, these results suggest that the addition of H9e adjuvant 
to PRRSV MLV vaccines can enhance protection against genetically distinct stains of PRRSV.   
 
4.3.2. Pigs vaccinated with MLV+H9e have increased vaccine virus circulation in the 
blood after vaccination 
H9e rapidly forms a gel once it is formulated with MLV. Therefore, we suspect that the H9e 
nanofiber network may act as a scaffold to prolong vaccine virus entry into the blood or enhance 
its replication within the host to enhance the vaccine’s protective effects. To determine if H9e 
adjuvant affects the viral load of the vaccine strain of PRRSV in vaccinated pigs, we measured 
circulating viral load in the serum of all pigs weekly. Interestingly, pigs vaccinated with 
MLV+H9e started to develop significantly higher levels of circulating virus two weeks after 
vaccination and reached an average maximum of 5.5-fold (9,057±402 TCID50 equivalent/ml ) 
higher virus titers than that in pigs vaccinated with MLV alone (1,638± 625 TCID50 equivalent 
/ml) on 21 DPV (Fig. 4.2A). By 28 DPV, the MLV virus was eliminated from the blood of pigs 
in all groups. Therefore, our results suggest that H9e may act to stabilize the MLV virus within 
the host and thus to increase the exposure of antigen to the host immune system. 
 
4.3.3. H9e-MLV vaccinated pigs show enhanced PRRSV-specific antibodies and 
PRRSV neutralizing antibodies 
To determine whether increased antigen exposure might lead to enhanced humoral and cellular 
immune responses in vaccinated pigs, we first evaluated antibody responses of pigs vaccinated 
with PRRSV MLV in the presence or absence of H9e. Serum samples were analyzed by 
commercial IDEXX PRRSV-specific antibody ELISA. By 14 DPV, 9 out of 10 pigs vaccinated 
with MLV+H9e were positive for PRRSV-specific antibodies (as defined by manufacturer at S/P 
ratio ≥ 0.4), compared with only 5 out of 10 pigs in MLV alone groups (Fig. 4.2B). Therefore, 
these results suggest that addition of H9e adjuvant results in the earlier onset of PRRSV 
antibodies than MLV alone. By 21 DPV, all vaccinated pigs had seroconverted to anti-PRRSV 






PRRSV MLV vaccination is characterized by generation of early non-protective antibodies 
specific to the nucleocapsid protein (as measured by IDEXX ELISA) and delayed generation of 
protective virus neutralizing antibodies. To determine if the H9e-mediated prolonged viremia 
affects the production of neutralizing antibodies as well, the PRRSV neutralizing antibody titers 
(VN titers) were analyzed. On 28 DPV, pigs vaccinated with MLV+H9e had similar VN titers to 
both VR-2332 and MN184A as that in pigs vaccinated with MLV-alone (Fig.4.2C). After 
homologous VR-2332 viral challenge, pigs vaccinated with MLV+H9e had significantly higher 
VN titer to VR-2332 and comparable VN titer to MN184A compared with pigs vaccinated with 
MLV alone (Fig. 4.2D).  However, all vaccinated pigs developed similar levels of VN titers after 
heterologous MN184A viral challenge (Fig. 4.2E).  Therefore, our results show that the addition 
of H9e hydrogel adjuvant can induce early on-set and enhanced antibody production over 
vaccinating pigs with MLV alone. 
 
4.3.4. Pigs vaccinated with MLV+H9e hydrogel have increased pro-inflammatory 
cytokines and reduced immunosuppressive cytokine secretion profiles 
Because we found that H9e can improve the humoral immune responses of pigs to the PRRS 
MLV vaccine, we next assayed the effects of H9e adjuvant on MLV-elicited cytokine profiles. In 
doing so, sera at 7 DPC were analyzed for the presence of IL-4, IL-8, IL-10, IFN-γ and TNF-α. 
As shown in Fig. 4.3, the levels of IFN-γ, but not TNF-α, in the sera from MLV+H9e vaccinated 
pigs was significantly higher than that in pigs vaccinated with MLV-alone after challenge 
(Fig4.3A,B). The levels of IL-4 and IL-8 in sera from pigs vaccinated with MLV+H9e were 
significantly higher than that from pigs vaccinated with MLV-alone when the pigs were 
challenged with VR-2332 PRRSV (Fig. 4.3C, D). Conversely, the secretion of 
immunosuppressive cytokine IL-10 in sera of MLV+H9e vaccinated pigs was reduced compared 
with that in the MLV-alone vaccinated pigs after challenge with both VR-2332 and MN184A 
(Fig. 4.3E). IL-10 expression levels of lung and TBLN MNCs also were analyzed at necropsy 
(15 DPC). As shown in Fig. 3e, after these cells were re-stimulated with either VR-2332 or 
MN184A in vitro, reduced IL-10 cytokine levels were observed in the supernatant of lung and 
lymph node MNCs of the pigs vaccinated with MLV+H9e. Therefore, our results suggest that 





4.3.5. Pigs vaccinated with MLV+H9e display decreased T-regulatory and increased 
Th/memory lymphocyte subpopulations 
To verify if the change in cytokine expression patterns was associated with changes in 
lymphocytes population, the frequencies of T-helper cells, cytotoxic T lymphocyte, Th/memory 
cells, T-regulatory cells and γδ T cells in blood, lung, and lymph nodes were evaluated using 
flow cytometry analysis. As shown in Fig. 4.4, a significant decrease of the T-regulatory (Treg) 
lymphocyte population (Fig. 4.4A) and increase of the Th/memory lymphocyte population (Fig. 
4.4B) was observed in the blood of pigs vaccinated with MLV+H9e than that in pigs vaccinated 
with MLV alone 4 weeks after vaccination.  The decrease of Treg lymphocyte population and 
increase of Th/memory lymphocyte population were also observed 14 DPC in pigs challenged 
with homologous VR-2332 or heterologous MN184A PRRSV in blood, TBLN, and lung MNC 
samples (Fig.4.4C, D). Additionally, we examined Th cells, CTL, γδ T cells and NK cell 
population before and after challenge and found no significant changes in any groups (data not 
shown). 
 
 4.4. Discussion  
Current commercial vaccines, both killed virus and modified live, are deficient in protecting 
swine herds from the consistently evolving field isolates of PRRSV [13]. One approach to 
improving PRRSV vaccine efficacy is the addition of immunomodulatory adjuvants including 
water-oil emulsions, aluminum, bacterial components, and polymers to killed or live modified 
PRRSV vaccines [14]. Interestingly, a new class of adjuvants, nanoparticles, has been shown to 
increase the cross-protection efficacy of killed PRRSV vaccines. In a recent study by Dwivedi et 
al, PLGA nanoparticle-entrapped killed PRRSV vaccine induces a cross-protective immune 
response against heterologous PRRSV challenge via enhanced innate and PRRSV-specific 
adaptive responses [15]. However, further studies are needed to reduce the cost and complexity 
of nanoparticle production before nanoparticle-based vaccines can be widely used as commercial 
products. Some more cost-effect commercial water-in-oil emulsion and polymers adjuvants, such 
as Montanide
TM
 ISA 15A and Gel01 ST, have also been utilized in live modified PRRSV 





50% of the antigen load had equivalent protection as pigs vaccinated with full dose of vaccine 
without the adjuvant.  
 
We recently reported that a biodegradable hydrogel could act as an adjuvant for killed swine 
influenza vaccines [10]. These previous results show that when H9e hydrogel was used in place 
of the supplied adjuvant of commercially available FluSure XP (Zoetis Inc), the H9e-adjuvanted 
vaccine led to significantly higher HAI titers and equivalent IgG antibody responses than the 
standard formulation of FluSure. Based on these results, we explored the ability of H9e hydrogel 
to act as an adjuvant for PRRS modified live virus vaccine and here we demonstrated that H9e 
hydrogels enhanced the vaccine’s protective effects for both homologous and heterologous 
PRRSV infection.  
 
H9e hydrogel forms a biodegradable nanofiber network under physiological conditions [16].  
Peptide-based nanofiber networks have been shown to aid in the controlled release of growth 
factors, therapeutics, and viruses [17-19]. Therefore, we hypothesized that this nanofiber 
network could create pockets that the vaccine virus could occupy and thus act as an antigen 
depot such that PRRS virus is presented slowly to the host immune system. We show here that 
the H9e had no virucidal effects and was able to facilitate increased PRRS vaccine virus 
presentation to the host, as shown by enhanced vaccine virus circulation in the blood (Fig. 4.2A). 
These results suggest high vaccine virus titers in the blood induced by MLV+H9e vaccination 
may facilitate the generation of an early and robust PRRSV immune response and provide better 
protection against genetically diverse strains of PRRSV.  
 
In addition to high circulating vaccine virus, pigs vaccinated with MLV+H9e had earlier on-set 
of PRRS-specific ELISA antibodies and enhanced neutralizing antibody titers to homologous 
virus. Previous reports have shown that PRRSV-specific antibodies can appear as soon as one 
week post-vaccination or challenge, however seroconversion is often observed between 14-21 
days post exposure [6,20]. Our results are consistent with these reports and we found that 







In order to gain insight into the immunologic mechanisms employed by the hydrogel adjuvant, 
cytokine expression levels after PRRSV challenge were compared among vaccinated groups of 
pigs. We found that the Th1-related cytokine IFN-γ in the sera of pigs vaccinated with 
MLV+H9e was significantly higher than that of pigs vaccinated with MLV alone after both 
homologous and heterologous challenges (Fig.4.3A, B). IFN-γ is a key cytokine that is 
associated with host cell-mediated immunity (CMI) response, which is secreted by natural killer 
cells and several different T cell subpopulations, and its expression is often decreased by PRRSV 
infection [21,22]. These studies suggest that decreased IFN-γ expression allows PRRSV to evade 
the host immune response and result in chronic PRRS infections. Interestingly, a recent study 
using two different PRRSV strains reported that systemic enhancement of IFN-γ further activates 
natural killers and T cell subpopulations creating a positive feedback loop for the rapid clearance 
of PRRSV [23]. Therefore, the elevated production of IFN-γ observed in the pigs vaccinated 
with H9e+MLV could explain the increased PRRS viral clearance and improved protective 
immune response we observed.  
 
The expression of inflammatory cytokine IL-8, but not TNF-α, was increased in pigs vaccinated 
with H9e-MLV when pigs were challenged with homologous VR-2332 virus (Fig. 4.3B and D).  
In previous studies, low serum IL-8 levels are related to persistent PRRSV infection, and 
elevated IL-8 levels in serum is correlated with the clearance of PRRS virus [24,25]. Although 
our results also indicated IL-8 may play a role in vaccination-induced clearance of PRRS virus, 
further experimentation is required to fully characterize the ability of H9e adjuvant to modulate 
IL-8 expression levels.  
 
The Th2-related cytokine IL-4 was increased in the sera of pigs vaccinated with MLV+H9e 
compared with the pigs vaccinated with MLV alone only after homologous VR-2332 challenge. 
IL-4 expression has been shown to control macrophage inflammatory activities in the pig [26]. 
While IL-4 expression levels in PRRSV-infected pigs can remain unaltered [27], recent studies 
suggest that natural PRRSV infection can significantly induce the expression of IL-4 [28], 
suggesting that PRRSV-mediated IL-4 induction may be strain dependent. In our hands, the 





pigs vaccinated with MLV+H9e than that of pigs vaccinated with MLV-alone. This indicates IL-
4 may play a positive role in the immune response to PRRSV infection. 
 
PRRSV infection or vaccination has been shown to induce a strong immunosuppressive response 
characterized by promoting the secretion of IL-10 to antagonize the protective Th1 immune 
response [29,30]. In our study, we found that the concentrations of IL-10 in the serum and tissues 
of pigs vaccinated with MLV alone were consistently higher than that from pigs vaccinated with 
MLV+H9e (Fig. 4.3E). IL-10 is mainly produced by a small subpopulation of T lymphocytes 
termed T-regulatory cells [31]. Consistent with IL-10 levels, the frequency of T regulatory cells 
in MLV+H9e vaccinated pigs was dramatically reduced in blood, lung MNCs, and TBLNs post 
infection (Fig. 4.4C). Therefore, it is likely that the reduced T-regulatory cell population and 
production of IL-10 may contribute to the enhanced Th1 response and efficient elimination of 






 T cells, which include T-helper, cytolytic, and memory properties, are a major type I 
IFN-γ cytokine secreting population [32]. In our study, pigs vaccinated with MLV+H9e 
generated significantly higher Th/memory cell populations both before and after challenge 
compared with the unvaccinated and MLV vaccinated pigs. This result is consistent with the 
observation that IFN-γ production is elevated in pigs vaccinated with MLV+H9e. The high 
frequency of functional T memory cells may contribute to rapid recall response for the quick 
elimination of subsequent PRRS virus exposure [33]. The ability of H9e adjuvant to shift MLV 
vaccine from mainly humoral, to a response having both humoral and cell-mediated immune 
responses suggest that CMI may be important for increased vaccine protection potential. Our 
results support the notion that MLV+H9e may act to enhance IFN-γ and reduce IL-10 production 
via increasing Th/memory and decreasing Treg lymphocyte populations, thereby causing a shift 
to a Th1-type immune response to provide a better protection against PRRSV infection. 
 
We have previously shown that flexible polymer adjuvants such Montanide™ Gel01 ST also can 
enhance the protective effects of modified live PRRSV vaccines: however, their enhanced 
protective effects are limited to homologous re-infection [11]. Interestingly, it was demonstrated 





mediated immunity but did not promote a stronger cellular-mediated immunity. Furthermore, 
Gel01 adjuvanted MLV did not show improved efficacy in reducing heterologous challenge-
induced viremia as compared with MLV alone. Thus, these results and our previous work 
suggest that the vaccine’s ability to generate a cellular-mediated immune response may be 
essential to mediate its cross-protective efficacy against PRRSV infection. 
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Figure 4.1. H9e adjuvant enhances protection efficacy of MLV to homologous and heterologous 
PRRSV infection in pigs. Pigs (3-week-old) were vaccinated with MLV or MVL+H9e and 
challenged with the VR-2332 or MN184A strain of PRRSV 28 days post vaccination. (A, B) 
Fold body weight gain during the duration of the experiment was determined. (C, D) Viral RNA 
in the serum (TCID50 equivalent /mL) was measured on 7 days post challenge (DPC) by RT-
PCR. Viremia data are shown as means ± SEM (n=5). Bracketed groups were compared and * 











Figure 4.2. Pigs vaccinated with MLV+H9e have increased vaccine virus circulation and 
produce an earlier on-set of PRRSV-specific antibodies. (A) Viral RNA of MLV vaccine virus in 
the serum (TCID50 equivalent /mL) was determined by RT-PCR weekly after vaccination with 
MLV, or MLV+H9e. Data were shown as mean ± SEM (n=5) ** p <0.01. (B) Serum from 
vaccinated pigs was assayed for PRRSV-specific antibodies with IDEXX HerdCheck ELISA kit. 
The threshold for seroconvertion was set at a sample-to-positive (s/p) ratio of 0.4 according to 
manufacturers’ instructions. (C-E) Serum samples were titrated individually in MARC-145 cells 
for the levels of anti-PRRSV neutralizing antibodies 28 days post vaccination (DPV) or 14 days 
post challenge (DPC) determined as the highest dilution that inhibited CPE. Data are shown as 












Figure 4.3. Pigs vaccinated with MLV+H9e have increased PRRSV-specific IFN-γ, IL-4, IL-8 
and reduced IL-10 cytokine secretion. Cytokine expression profiles in the sera of pigs 7 days 
post challenge (DPC) were examined by quantitative ELISA, (A) IFN-γ (B) TNF-α (C) IL-4 and 
(D) IL-8. (E) IL-10 concentrations in serum samples and supernatants of PBMCs and lung 
MNCs which were collected at necropsy (15 DPC) and restimulated with corresponding PRRSV 





Figure 4.4. Pigs vaccinated with MLV+H9e have decreased T-regulatory and increased 





FoxP3, and CD25. (A) Shown are the percentages of T-reg cells that were triple-positive for 
CD4/FoxP3/CD25 28 days post vaccination (DPV) and (C) 14 days post challenge (DPC). (B) 
Also shown are the percentages of Th/memory cells that were double-positive for CD4/CD8 on 
28 DPV and (D) on 14 DPC. Data is shown as mean ± SEM (n=5). Bracketed groups were 









Chapter 5 - Comparison of immune responses between infection 
with a Chinese highly-pathogenic strain of PRRSV vs the US 
NADC-20 strain  
Abstract: The differences in pig immune responses elicited by a Chinese highly-pathogenic 
strain of PRRSV (HP-PRRSV) and the American NADC-20 strain were compared in this study. 
Pigs infected with HV-PRRSV, rescued from an infectious clone of Chinese HP-PRRSV, 
exhibited significantly higher fevers, more body weight loss, and more severe histopathogical 
lung lesions than infection with U.S. NADC-20 strain. The HV-PRRS virus showed significant 
higher proliferation ability in vivo than NADC-20 evidenced by more than 10-fold increased 
viral load in the serum at 9 day post infection (DPI). However, the high proliferation ability of 
HV-PRRSV did not enhance the induction of PRRSV-specific ELISA antibodies. NADC-20 
infected pigs showed significantly higher Ab titers than HV-PRRSV infected pigs at 9 DPI. 
Infection with HV-PRRSV induced a significantly higher levels of TNF-α and IL-10 in both 
serum and lung tissues and significantly higher IFN-α and IFN-γ in the serum. Flow cytometry 
analysis showed that HV-PRRSV infected pigs generated significantly higher frequencies of NK 
cells in the peripheral blood and Th/memory, CTLs, and T-reg cells in the lung tissue as 
compared with NADC-20 infected pigs. Thus, this study demonstrates that different immunity 
profiles were elicited by HV-PRRSV and NADC-20, and these differences may contribute to the 













 5.1. Introduction 
Highly-pathogenic PRRS virus (HP-PRRSV) belongs to type 2 genotype (North American, 
prototype strain VR-2332) of PRRSV, which is a member of the genus Arterivirus, family 
Arteriviridae. HP-PRRSV is characterized by high fever and high rates of morbidity and 
mortality [1]. This novel and highly virulent variant of PRRSV, which first emerged in China in 
2006, has rapidly spread to most countries in Southeast Asia [2]. HP-PRRSV exhibits more 
extensive tissue tropism than classic PRRSV [3]. Besides lymphoid tissues, IHC examination 
showed that HP-PRRSV antigen can also be detected in the tissues including trachea, esophagus, 
liver, kidney, cerebellum, stomach, and intestine, which proves its highly pathogenicity to pigs 
[4].  
 
Compared with the prototype of type 2 genotype strain VR-2332, HP-PRRSV can elicit strong 
immune responses by the evidence of a striking elevation in the level of cytokines associated 
with both innate and adaptive immunity in HP-PRRSV infected pigs [5]. However, VR-2332, 
which was first isolated in 1987, only leads to mild clinical symptoms and does not circulate in 
the field any more [6]. NADC-20 is a virulent North American PRRSV strain, which was first 
isolated in an “atypical PRRSV abortion storm” in 2001 [7]. It has been widely used for viral 
challenge to evaluate the efficacy of PRRSV vaccines in the United States [8]. Compared with 
the other strains of PRRSV in the U.S., NADC-20 can lead to clinical fever (≥ 40°C) and more 
robust immune responses after infection of pigs [8]. Therefore, analysis of the host immune 
responses elicited by two virulent strains of PRRSV will contribute to better understanding of the 
pathogenesis of highly pathogenic PRRSV and facilitate more effective vaccine development. In 
this study, 7-week old pigs were infected with the HV-PRRSV or NADC-20 strain of  
PRRSV and the clinical symptoms and the profiles of host immune response were compared. 
 
 5.2. Materials and Methods 
5.2.1. Cells and virus  
MARC-145 cells were maintained in modified Eagle’s medium (MEM) supplemented with 7% 





with 5% CO2. For virus infection and titration, MEM supplemented with 2% FBS was used. 
HV-PRRSV was rescued from highly pathogenic PRRSV infectious clone [9], and propagated 
on MARC-145 cells for three passages before use. PRRSV NADC-20 was a kind gift from Dr. 
Lager Kelly (National Animal Disease Center, USDA-ARS, Ames, IA). 
5.2.2. Experiment design 
Fifteen conventional Large White-Duroc crossbred weaned specific-pathogen free piglets (7 
weeks of age) were tested to be PRRSV negative by ELISA and RT-PCR and were divided into 
3 groups.  Five pigs were infected with 2x10
5
 TCID50/pig NADC-20 and housed for 10 days 
before the necropsy within the Large Animal Research Center facility (Bio-safety Level 2) at 
Kansas State University. Another 10 pigs were divided into two groups (n=5/group) and housed 
in separate rooms within Biosafety Research Institute (Bio-safety Level 3) Kansas State 
University. One group of pigs was infected with 2x10
5
 TCID50/pig HV-PRRV on day 0, and 
another group of pigs received MEM medium and worked as uninfected controls throughout the 
study. Weight measurements and blood samples were collected every 3 days and rectal 
temperature and clinical signs were monitored daily. All pigs were humanly euthanized at 10 
days post infection (DPI). Thymic and lung tissues were weighed and compared with total body 
weight to evaluate thymic atrophy and lung inflammation induced by the viral infection. Serum 
samples were used to measure viral load, PRRSV-specific antibodies, and cytokine expression. 
All animal experiments were approved by the Institutional Animal Care and Use Committee at 
Kansas State University. 
 5.2.3. Collection of blood samples for analysis 
Blood was collected from each pig every 3 days.  Serum was separated from clotted blood and 
preserved at -20°C. Serum was used for evaluation of viral titer and PRRSV-specific ELISA 
antibody titers (Herdchek Porcine Reproductive and Respiratory Syndrome Antibody test Kit, 
IDEXX Laboratories) as previously described [10]. Pig serum at 7 DPI and the supernatant of 
lung homogenates were used to analyze cytokine expression [11]. IFN-α and IFN-β ELISA kits 
were purchased from Abcam (Abcam, Cambridge, MA). IL-4, IL-8, IL-10, IFN-γ and TNF-α 
were purchased from Invitrogen (Life Technologies, Carlsbad, CA). Procedures were performed 





concentration by applying a linear regression formula calculated from the results of the standards 
provided in each kit. 
 
Total RNA was extracted from serum and One-step Taq-Man qPCR was performed to calculate 
PRRSV RNA copy number in the serum sample according to the brochure of manufacture (EZ-
PRRSV
TM
 MPX4.0 Real Time RT-PCR, Tetracore Inc., Rockville, MD). A standard curve was 
constructed by preparing serial dilutions of an RNA control, supplied in the RT-PCR kit, and 
virus quantities of unknown samples were determined by linear extrapolation of the Ct value 
plotted against the standard curve. 
 
Hepatized whole blood was subjected to flowcytometry analysis to determine different 































The mouse anti-pig TcR1N4 antibody was purchased from VMRD (Pullman, WA), and all other 
antibodies were purchased from BD Biosciences (San Jose, CA). Immuno-stained cells were 
acquired using a FACS Caliber (BD Biosciences) flow cytometer as described previously[11]. 
Briefly, PBMC was treated with 2% pig serum to block Fc receptors. Cells were then stained 
with an appropriate Ab which was either directly conjugated to a specific fluorochrome or with a 
purified Ab to pig specific immune cell surface marker (TcR1N4). For cells stained with a 
purified Ab, labeled cells were treated with anti-species isotype specific secondary Ab 
conjugated with fluorochrome. Finally, cells were fixed with 1% paraformaldehyde before flow 
cytometer reading. Percentages of each lymphocyte population were analyzed by 100,000 unique 
events using FlowJo software (Tree Star, Inc., OR, USA).  
 
5.2.4. Histopathological analysis 
Pigs were humanely euthanized at 10 DPI as approved by the Kansas State University 
Institutional Animal Use and Biosafety Committee. The lungs were macroscopically and 
microscopically evaluated as previously described [12].  Briefly, the dorsal and ventral surfaces 





consolidated. Individual lobe scores were used to determine an overall lung score representing 
the percentage of lung with pneumonia. Sections of each of the 4 lobes of the right lung were 
fixed in 10% buffered neutral formalin, paraffin-embedded, sectioned, and stained with 
hematoxylin and eosin (H & E).  Scoring of microscopic lung pathology was done in a blinded 
fashion by a veterinary pathologist in the Kansas State Veterinary Diagnostic Laboratory.  
Grading was on a 4 point scale as previously described [12]. 
5.2.5. Statistical analysis 
All data were expressed as the mean value of five pigs ± SEM. The differences in the level of 
humoral response, body temperature and body weight, viral titer, lung score, cytokine 
production, and percentage of lymphocyte subpopulations among each group were determined 
by the one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s test using 
Sigmaplot 11 software (Systat Software Inc., San Jose, CA). Differences were considered 
statistically significant when p<0.05. 
 
 5.3. Results 
5.3.1. Pigs infected with HV-PRRSV had significantly higher fever and less body 
weight gain as compared with NADC-20 infected pigs 
HP-PRRSV infection is characterized by high fever, high percentage of morbidity and mortality 
in pigs [1]. Thus, the rectal temperature of pigs was monitored daily. The average body 
temperature in HV-PRRV infected pigs was above 40°C, the cutoff of clinical fever throughout 
the study, and it was significantly higher than that in NADC-20 infected pig except at 7 DPI 
(Fig.5.1A). The NADC-20 infected pigs developed clinical fever only at 1 and 7 DPI, with the 
mean body temperature on these two days being 40.5°C. One pig within the HV-PRRV infection 
group died at 3 DPI and two other pigs were euthanized due to severe weakness and moribund 
condition at 6 DPI (Fig. 5.1B). The clinical signs of HP-PRRSV-infected pigs included 
dehydration, respiratory distress, shivering, and inability to bare weight on front limbs. Two of 
the dead pigs developed cutaneous hemorrhages and cyanotic extremities on the edges of their 
ears. None of pigs in the NADC-20 infection group or control group died or had to be 





symptoms were observed. HV-PRRSV infected pigs rapidly lost their body weight as compared 
with the naïve and NADC-20 infected pigs, but their average body weight returned to the starting 
weight by 10DPI (Fig.5.1C).  
5.3.2. HV-PRRSV infection led to severe thymus atrophy and lung inflammation in 
pigs  
Severe lesions including marked interstitial pneumonia, lymphadenopathy and thymic atrophy 
were observed in HV-PRRSV infection pigs. Postmortem finding include pulmonary edema, 
hematoma, pleural adhesion, peritoneal and pericardial effusions, and renal petchia. Pigs in HV-
PRRSV infection group showed more severe and extensive pneumonia than NADC-20 infected 
pigs, and the macro- and histo- pathological lung scores in this group were significantly higher 
than NADC-20 infected group (Fig.5.2A, B). No pathologic lesions were identified in control 
pigs.  
 
HV-PRRSV was previously reported to lead to thymus atrophy [3]. To confirm this, the ratio of 
thymus/body weight was calculated to evaluate the thymus atrophy at necropsy. The ratio of 
thymus/total body weight of pigs in HV-PRRSV infection group was significantly lower as 
compared with NADC-20 infection group (Fig.5.2C), which supports that severe thymus atrophy 
occurs in HP-PRRSV infected pigs. In contrast, the thymus weights of pigs in the NADC-20 
infected group showed the similar average weight to the naïve pigs. The ratio of lung/total body 
weight was used to evaluate the inflammation status after virus infection. The ratio was 
significantly higher in HV-PRRSV infected pigs than NADC-20 infected pigs (Fig.5.2D), and 
there was no difference in the ratio between NADC-20 infected pigs with naïve pigs. The above 
data showed that HV-PRRSV infection lead to significant thymus atrophy and lung inflammation 
as compared with NADC-20 infection in pigs.   
5.3.3. HV-PRRSV infection showed enhanced viral titers in pigs but did not elicit 
earlier or higher PRRSV-specific IDEXX ELISA Antibodies than NADC-20 infected 
pigs 
HP-PRRSV was previously reported to have higher proliferation ability than the classic PRRSV 





pigs than NADC-20 infected pigs at 3 DPI, but the difference was not significant (Fig.5.3A). At 
6 DPI, the viremia in the blood was similar (average 2.5x10
6
 RNA copy number/μl) in both 
challenge groups. By 9 DPI, the viral titer in NADC-20 infected pigs dropped 10 fold, whereas 
the serum virus copy number of HV-PRRSV infected pigs increased to 3x10
6
 RNA copy 
number/μl. The above results showed that HV-PRRSV has significantly higher proliferation 
ability than NADC-20. 
 
PRRSV-specific antibodies elicited by the two strains of PRRSV were measured by IDEXX 
ELISA kit. The high proliferation ability of HP-PRRSV did not elicit earlier or higher titer of 
PRRSV-specific Ab. Indeed, at 9 DPI, the average ELISA antibody titer in NADC-20 infected 
pigs was significantly higher than that in HV-PRRSV infected pigs (Fig.5.3B).  
5.3.4. Cytokine expression in the serum and lungs was up-regulated by HV-PRRSV 
compared with NADC-20 infection 
Sera collected at 7 DPI and the supernatant of lung homogenates collected at 10 DPI were 
analyzed for innate cytokine (TNF-α, IFN-α, IFN-β, and IL-8) and adaptive cytokine (IL-10, IL-
4, and IFN-γ) expression. As for the innate cytokines, HV-PRRSV infection induced 
significantly higher TNF-α level in both serum and lung samples from the pigs (Fig.5.4A, B). 
HV-PRRSV infection also induced significantly higher IFN-α in the serum but significantly 
lower IFN-α in the lung samples as compared with NADC-20 infected pigs. There was no 
significant difference between the two infected groups for the expression of IFN-β and IL-8 in 
serum and lung samples. As for the adaptive cytokines, HV-PRRSV infection elicited 
significantly higher IL-10 and IFN-γ in the serum of pigs, and significantly higher IL-10 in the 
lung samples sample as compared with NADC-20 infected pigs (Fig.5.4A, B).  
5.3.5. Higher-frequency of NK cells, Th/memory, CTLs and Treg cells, but reduced 
total T cells were observed in HV-PRRSV infected as compared with NADC-20 infected 
pigs 
The frequency of various lymphocyte populations after infection was monitored by flow 
cytometry. In the blood, the frequency of total T cells and NK cells in HV-PRRSV infected pigs 





infection significantly decreased the Th/memory cell population in the blood samples of pigs as 
compared with NADC-20 infected pigs. There were no significant differences among the groups 
for all other cell populations assayed. In the lung, the frequency of Th/memory, CTLs, and T-reg 
cells in HV-PRRSV infected pigs were significantly higher than that in NADC-20 infected pigs 
(Fig.5.5B). However, the total T cell population in HV-PRRSV infected pigs was significantly 
lower than that in NADC-20 infected pigs. There was no significant difference for the percentage 
of T-helper cells and γδ T cells between two infected groups in the lung samples.  
 
 5.4. Discussion  
Classic PRRSV causes mild clinical symptoms and leads to abortion in sows and death of 
piglets. In contrast, highly pathogenic strains of PRRSV lead to death at all ages of pigs with 
100% morbidity and 20% of mortality [1]. Several research groups reported that high fever and 
increased tissue atrophy were associated with the high mortality rate caused by HP-PRRSV 
[3,14,15]. HP-PRRSV was also reported to elicit elevated expression of inflammatory cytokines, 
which may partially explain the high fever developed after viral infection [5]. However, the 
difference of host immune responses induced by HP-PRRSV and classic PRRSV was seldom 
explored. In one study, HP-PRRSV was reported to replicate in swine with at least 100-fold 
increased kinetics over U.S. strain VR-2332, and elicit a striking elevation in the levels of 
cytokines associated with both innate and adaptive immunity [5]. VR-2332 was isolated in 1987 
and it is the parental strain of one of the current PRRS modified live vaccines. This virulent 
strain of PRRSV can only cause mild clinical symptoms and moderate lung damage. NADC-20 
was first isolated in an “atypical PRRSV abortion storm” in 2001, and it can lead to high fever (≥ 
40°C) and severe lung and lymph node tissue damage [7]. Therefore, in this study, we compared 
the host immune responses elicited by Chinese HP-PRRSV and US NADC-20. 
 
The HP-PRRSV was reported to induce high fever, loss of body weight, severe respiratory 
symptoms and high mortality. In our study, the pig body temperature in HV-PRRSV infected 
pigs was higher than 40°C during the duration of the infection, which may partially contribute to 
the dehydration and respiratory distress (Fig.5.1A). The HV-PRRSV infection led to significant 





lost an average of 10% of their body weight at 3 and 6 DPI, however, body weight returned to 
original weight by 10 DPI (Fig.5.1C). The body weight of NADC-20 infected pigs increased 
consistently after infection, although it was significantly lower as compared with the control pigs 
at 6 and 10 DPI (Fig.5.1C). Consistent with a previous report [5], HV-PRRSV infected pigs also 
showed more severe clinical symptoms including cutaneous hemorrhages and cyanotic 
extremities on the edge of ears (“blue ear”) and higher mortality rate (3/5 pigs died).  
 
HV-PRRSV led to significant thymus atrophy compared with NADC-20 infection. The ratio of 
thymus/total body weight was significantly lower in HV-PRRSV infected pigs as compared with 
NADC-20 infected pigs (Fig.5.2C). Thymus is the primary lymphoid tissue, in which T-
lymphocytes mature and constitute the peripheral T-cell repertoire responsible for directing 
many facets of the adaptive immune responses. The malfunction/atrophy of thymus leads to the 
depletion of T lymphocytes, which was consistent with the significant loss of total T 
lymphocytes in the lung analyzed by the flowcytometry. In contrast, the ratio of lung/total body 
weight was significantly higher in HV-PRRSV infected pigs as compared with NADC-20 
infected pigs (Fig.5.2D), which indicated more inflammatory responses after HV-PRRSV 













), were significantly higher after HV-
PRRSV infection as compared with NADC-20 infection.  
 
HP-PRRSV has showed higher proliferation ability than classic PRRSV both in vitro and in vivo 
[5]. In this study, both HV-PRRSV and NADC-20 showed similar proliferation ability within the 
first 6 days of infection. Interestingly, by 9 DPI the viremia in NADC-20 infected pigs declined 
while the viremia of HV-PRRSV infected pigs was still increasing (Fig.5.3A). In a study by Guo 
et al [5], the virus titer and virus load in the serum were significantly higher after rJXwn6 HP-
PRRSV infection as compared with VR-2332 infection from 2 to 11 DPI. The discrepancy of the 
verimia level could be due to the different strains of PRRSV was used in each study, and the 
NADC-20 used in our study is more virulent than VR-2332. However, the high proliferation 
ability of HV-PRRSV did not correlate with higher titer of PRRSV-specific IDEXX ELISA 
antibody response, in that the average antibody titer in NADC-20 infected pigs was significantly 





antibody response against N proteins of PRRSV, which has no protective ability to the PRRSV 
infection although it has been widely used for the diagnosis in the field [16]. The different ability 
to induce PRRSV IDEXX ELISA Ab between HP-PRRSV and classic PRRSV may contribute to 
the pathogenesis of viruses, and need further exploration.   
TNF-α is a proinflammatory cytokine, which plays a very important role in regulation of immune 
responses, fever development (inflammation), and cell apoptosis [17]. Several studies showed 
that PRRSV down-regulated TNF-α production in the early stage of infection, which may be 
used by virus to circumvent infected cell apoptosis [18,19]. At the late stage of PRRSV infection, 
the peak of both apoptotic cells and viral antigen expression were observed in lymph nodes and 
tonsils of infected animals [20]. In our study, HV-PRRSV induced significantly higher TNF-α in 
both serum and lung samples at 7 DPI, and the high level of TNF-α expression correlates with 
the high level of viremia. The coincidence between high expression of TNF-α and high level of 
viremia at the late stage of PRRSV infection may indicate that PRRSV induces TNF-α mediated 
cell apoptosis to release virion progeny to infect other vulnerable cells.  
Previous studies showed that infection with several classic strains of PRRSV virus induced 
delayed or failed production of detectable serum IFN-α level [21-23]. In contrast, HV-PRRSV 
infection induced significantly higher IFN-α in the serum of pigs but significantly lower levels in 
the lung samples. Working as a potent antiviral molecule, IFN-α was reported to significantly 
inhibit PRRSV replication and enhance cellular-mediated immunity (IFN-γ responses) [24,25]. 
However, the elevated serum IFN-α has no effect on virus clearance by the evidence of high 
level of viremia in HV-PRRSV infected pigs at 9 DPI (Fig.5.3A and Fig.5.4A). Also, the low 
level of IFN-α expression in the lung tissue after HV-PRRSV infection did not lead to the 
decreased IFN-γ production as compared with NADC-20 infected pigs. Therefore, the role of 
IFN-α in the pathogenesis of PRRSV and host immunity to combat PRRSV needs to be further 
explored.  
HV-PRRSV also elicited a significant elevation of adaptive immunity cytokines in the serum 
samples, such as IL-10 and IFN-γ, and significantly higher IL-10 in the lung samples (Fig.5.4A 
and B). Induction of IL-10 following PRRSV infection is believed to be focal mechanism 





production of IL-10 in the early stage of PRRSV infection is associated with a wide array of 
PRRSV-induced immunomodulatory activities [24,26]. Consistent with previous studies, the 
expression of IL-10 in the serum and lung samples was significantly higher in HV-PRRSV 
infected pigs as compared with NADC-20 infected pigs [5]. The high level expression of IL-10 
correlates with high titer of viremia in this study and PRRSV antigen gene expression in the 
lungs and tonsils of PRRSV infected pigs in previous studies [22]. Some strains of modified live 
PRRSV vaccines also induced IL-10 production in vaccinated pigs, which may partially 
contribute to the failure of PRRSV vaccination [24]. Therefore, how to circumvent the inhibitory 
effect of IL-10 in the early stage of PRRVS vaccination/infection could be a challenge for the 
PRRSV vaccine development. 
 
IFN-γ is a key cytokine that is associated with host cell-mediated immunity (CMI) response, 
which is secreted by natural killer cells and several different T cell subpopulations. Significantly 
higher levels of IFN-γ in the serum was found in pigs infected with HV-PRRSV as compared 
with NADC-20 infected pigs (Fig.5.4A), which was associated with a significantly higher 
percentage of NK cells in the blood  (Fig.5.5A). The coincidence of high levels of IFN-γ 
expression and the high percentage of NK cells may indicate that the production of IFN-γ at this 
stage might be a result of the innate immune response, most likely from antigen-stimulated NK 
cells [27]. However, the high level of IFN-γ in the serum did not lead to the decreased level of 
viremia. In contrast, the level of viremia in HV-PRRSV infected pigs was significantly higher 
than NADC-20 infected pigs. Therefore, the role IFN-γ plays in the protection to PRRSV 
infection at this stage is questionable. 
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Figure 5.1. High fever, high mortality rate, and loss of body weight after HV-PRRSV infection. 
(A) Rectal temperature of all pigs was monitored daily after PRRSV infection. (B) Survival rate. 
(C) Fold total body weight gain during the duration of the experiment was calculated by 







Figure 5.2. Thymus atrophy and lung inflammation caused by HV-PRRSV. Thymus weight and 
lung weight to body weight ratios of HV-PRRSV infected pigs showed pronounced thymus 
atrophy (A) and lung inflammation (B) as compared with NADC-20 infected pigs. Each bar 








Figure 5.3. Viremia and PRRSV-specific ELISA Ab profiles after PRRSV infection. (A) 
PRRSV Viral RNA in the serum was determined by qPCR. (B) Pig serum was assayed for 
PRRSV-specific antibodies with IDEXX HerdCheck ELISA. The threshold for seroconvertion 
was set at a sample-to-positive (s/p) ratio of 0.4 according to manufacturers’ instructions. Each 
bar represents the average of five pigs ± SEM. *p<0.05. 
 
 
Figure 5.4. Serum immune cytokine profiles after PRRSV infection. Cytokine expression 
profiles in the sera of challenge pigs 7 days post infection (DPI) and supernatants of lung 
homogenates were tested by quantitative ELISA. Data were shown as mean ± SEM for 5 pigs 
per group. One asterisk denotes a statistically significant difference (P <0.05), and “NS” denotes 







Figure 5.5. T lymphocyte population profiles after PRRSV infection. Whole blood and lung 
samples were collected at necropsy and were used to analyze the percentage of different T 
lymphocyte populations by flow cytometer according to their phenotypes. Data were shown as 
mean ± SEM for 5 pigs per group. One asterisk denotes a statistically significant difference (P 





Chapter 6 - Pigs immunized with Chinese high pathogenic PRRSV 
modified live vaccine are protected from challenge with North 
American NADC-20 PRRSV strain  
 
Abstract: Porcine reproductive and respiratory syndrome (PRRS) causes huge economic loss to 
the swine industry worldwide, and vaccination is the most effective way to control the disease. 
Recently, strains of highly pathogenic PRRSV (HP-PRRSV) have appeared in China and 
Southeast Asia. Traditional type 2 modified live virus (MLV) vaccines developed in the United 
States offer no protection to these HP-PRRSV strains. Modified live vaccines specific to HP-
PRRSV strains available in China are reported to provide protection to the Chinese strains of 
HP-PRRSV, however, the efficacy of Chinese HP-PRRSV vaccines to current circulating North 
American PRRSV viruses has not been reported. The aim of this study is to investigate whether 
pigs challenged with the North American NADC-20 strain are protected by vaccination with 
Chinese MLV HP-PRRSV vaccines. On day 0, pigs were vaccinated with Chinese JXA1-R-
MLV vaccine or a mock vaccine. After 28 day post vaccination, pigs were challenged with 2x10
5
 
TCID50 NADC-20 PRRSV. The MLV-HP-PRRSV vaccinated pigs showed good protection to 
NADC-20 challenge as shown by reduced virus-induced-fever, reduced lung pathology scores, 
and lower NADC-20 virus load in the blood. PRRSV-specific Ab, as measured by IDEXX 
ELISA, appeared one week after vaccination and virus neutralizing Abs were detected 4 weeks 
post vaccination. Vaccinated pigs developed high titers of viral neutralizing Abs to NADC-20, 
JXA1-R, and HV-HP-PRRSV (a highly pathogenic strain of PRRSV). The secretion of innate 
cytokines IFN-α and IFN-β were elevated in the lung tissue at necropsy, but the level TNF-α was 
decreased in the lung tissue of MLV-HP-PRRSV vaccinated animals. In summary, our study 
provides the first evidence that Chinese HP-PRRSV vaccines confer protection to the North 
American PRRSV strain NADC-20. Therefore, the availability of Chinese HP-PRRSV vaccines 
in North America may not only act to increase the preparedness of possible transmission of HP-






 6.1. Introduction 
Porcine reproductive and respiratory syndrome is caused by porcine reproductive and respiratory 
syndrome virus (PRRSV), which is a member of the genus Arterivirus, family Arteriviridae. 
PRRSV causes respiratory distress in pigs of all ages and reproductive failure in sows, and pigs 
infected with PRRSV have enhanced susceptibility to secondary microbial infections [1]. 
PRRSV is a highly devastating swine disease, which causes $664 million in losses within US 
annually, an increase from the $560 million annual cost estimated in 2005 [2]. Since 2006, 
highly pathogenic PRRSV (HP-PRRSV) has been reported in China in which infected pigs 
developed predominant clinical signs including high fever (≥42°C), anorexia, listlessness, red 
discoloration of skin, respiratory distress and very high morbidity and mortality rate [3]. So far, 
this virus has rapidly spread to most countries in Southeast Asia including Cambodia, Laos, 
Philippines, Bhutan, Myanmar, Thailand, South Korea and Russia [4]. The first HP-PRRSV 
isolate JXA1 (Genbank ID: EF112445.1) in 2006 shares 91% genome similarity with the 
prototype of type 2 genotype strain VR-2332 (Genbank ID: AY150564.1). However, during the 
prevalence of HP-PRRSV from 2006 to 2009, the commercial type 2 PRRSV vaccines failed to 
provide protection of pigs to HP-PRRSV infection until the first Chinese HP-PRRSV MLV 
JXA1-R was used in the field in 2009 [5,6]. Subsequently, two additional commercial HP-
PRRSV MLV vaccines, TJM-F92 and HuN4-F112, were also launched into the Chinese market 
[7].  
Currently, traditional type 2 PRRSV live attenuated vaccines including Ingelvac® PRRS MLV 
have been widely used in North American and European countries. Based on the fact that 
traditional PRRV MLVs failed to provide protection to HP-PRRSV, the availability of Chinese 
HP-PRRSV vaccines may not only act to increase the preparedness of possible transmission of 
HP-PRRSV to these countries, but also may help protect pigs against PRRSV strains native to 
them. However, the efficacy of HP-PRRSV vaccines to the circulating field PRRSVs outside 
China has never been explored. To answer this question, pigs were vaccinated with the HP-
PRRSV-MLV vaccine and then challenged with the North American NADC-20 strain of PRRSV 





 6.2. Materials and Methods 
 
6.2.1. Cells and virus  
MARC-145 cells were maintained in modified Eagle’s medium (MEM) supplemented with 7% 
fetal bovine serum (FBS) containing 100U penicillin/ml and 100ug streptomycin/ml at 37°C 
with 5% CO2. For virus infection and titration, MEM supplemented with 2% FBS was used. 
NADC-20 PRRSV was a kind gift from Dr. Lager Kelly (National Animal Disease Center, 
USDA-ARS, Ames, IA), and JXA-1r HP-PRRSV vaccine was a kind gift from Guangdong 
Dahuanong Animal Health Product Co., Ltd. 
 
6.2.2. Pigs, vaccination and challenge 
Twenty conventional large White-Duroc crossbred weaned specific-pathogen free piglets (3 
weeks of age) were divided into four groups within the Large Animal Research Center (LARC) 
facility, Kansas State University. These piglets were confirmed sera-negative for antibodies to 
PRRSV by ELISA and PRPSV-free in the blood by RT-PCR. Pigs were allowed to acclimate for 
an additional week before initiation of the experiment. Pigs were first divided into two groups 
(10 pigs /group) and kept in two separate pens. 
 
Pigs in the first group were immunized intramuscularly on day post-vaccination (DPV) 0 with 
1x10
6
 TCID50 JXA-1r MLV HP-PRRSV vaccine Pigs in another group of pigs remained 
unvaccinated. After 4 weeks, 5 pigs in the vaccinated group were switched with 5 pigs in the 
unvaccinated group. Ten pigs (5 vaccinated and 5 unvaccinated pigs) were then challenged with 
NADC-20 (2x10
5
 TCID50/ pig), and other 10 pigs remained unchallenged. Necropsy was 
performed at 10 days post-challenge (DPC). Pigs were monitored for rectal temperature for the 
first 9 days after challenge and body weight once a week after vaccination and every 3 days after 
viral challenge.  
6.2.3. Collection of blood samples for analysis 
Pig blood was collected every 7 days after vaccination and every 3 days after viral challenge.  
Serum was separated from clotted blood and preserved at -20°C. Serum was used for evaluation 





Respiratory Syndrome Antibody test Kit, IDEXX Laboratories) as previously described [8]. Pig 
serum at 6 dpi and the supernatant of lung homogenates were used to analyze cytokine 
expression [9]. IFN-α and IFN-β ELISA kits were purchased from Abcam (Abcam, Cambridge, 
MA); and IL-4, IL-8, IL-10, IFN-γ, and TNF-α were purchased from Invitrogen (Life 
Technologies, Carlsbad, CA). Procedures were performed as per the manufacturer’s instructions. 
For a given sample, the OD450 was then transformed to concentration by applying a linear 
regression formula calculated from the results of the standards provided in each kit. 
 
Total RNA was extracted from serum and One-step Taq-Man qPCR was performed to calculate 
PRRSV RNA copy number in the serum sample according to the brochure of manufacture (EZ-
PRRSV
TM
 MPX4.0 Real Time RT-PCR, Tetracore Inc., Rockville, MD). A standard curve was 
constructed by preparing serial dilutions of an RNA control, supplied in the RT-PCR kit, and 
virus quantities of unknown samples were determined by linear extrapolation of the Ct value 
plotted against the standard curve. 
6.2.4. Virus neutralizing antibody titer 
Serum samples were heat inactivated (56°C, 30min) and serially diluted before the titration. The 
serial dilutions of serum were mixed with equal volume of PRRSV strains: NADC-20, JXA1-R 
(parental strain of HP-PRRSV MLV vaccine) and HV-PRRSV (a Chinese HP-PRRV rescued 
from an infectious clone) containing 200 TCID50 of virus. After incubation at 37°C for 1h, the 
mixtures were transferred to MARC-145 monolayers in 96-well plates and incubated for an 
additional 72h at 37°C in a humidified atmosphere containing 5% CO2. Cells were then 
examined for cytopathic effects (CPE). CPE was used to determine the end-point titers that were 
calculated as the reciprocal of the highest serum dilution to neutralize 200 TCID50 of PRRSV in 
90% of the wells. 
6.2.5. ELISpot assay  
Half million PBMCs were plated in enriched RPMI in a 96-well multiscreen plate (Millipore, 
Billerica, MA) pre-coated overnight with capture IFN-γ mAB (BD pharMingen, San Diego, CA). 
PBMCs were re-stimulated with NADC-20 at 0.1MOI for 24h at 37°C. IFN-γ-secreting cells 
were detected by biotinylated anti-pig IFN-γ detection antibody and visualized using the 





were subtracted from the respective counts of the unstimulated cells and the immune responses 
were presented as the mean numbers of antigen-specific IFN-γ-secreting cells per 10
6
 PBMCs 
from duplicate wells of each sample.  
6.2.6. Histopathological analysis 
Pigs were humanely euthanized on DPC 10 as approved by the Kansas state University 
Institutional Animal Use and Biosafety Committee. The lungs were macroscopically and 
microscopically evaluated as previously described [10].  Briefly, the dorsal and ventral surfaces 
of each lung lobe were given a score representing the approximate proportion that was 
consolidated. Individual lobe scores were used to determine an overall lung score representing 
the percentage of the total lung that was macroscopically pneumonic. Sections of each of the 4 
lobes of the right lung were fixed in 10% buffered neutral formalin, paraffin-embedded, 
sectioned, and stained with hematoxylin and eosin (H & E).  Scoring of microscopic lung 
pathology was done in a blinded fashion by a veterinary pathologist in the Kansas State 
Veterinary Diagnostic Laboratory.  Grading was on a 4 point scale as previously described [10]. 
6.2.7. Statistical analysis 
All data were expressed as the mean value of five pigs ± SEM. The differences in the level of 
body temperature, lung pathology score, humoral response, cytokine production and viremia 
among each group were determined by the one-way analysis of variance (ANOVA) followed by 
post-hoc Tukey’s test using Sigmaplot 11 software (Systat Software Inc., San Jose, CA). 
 
 6.3. Results 
6.3.1. JXA1-R MLV vaccination protects pigs from hyperpyrexia induced by NADC-20 
challenge but leads to decreased body weight gain  
NADC-20 is a virulent North American PRRSV strain and was first isolated in an “atypical 
PRRSV abortion storm” in 2001 [11]. It has been used for viral challenge to evaluate the efficacy 
of PRRSV vaccines in the United States [12]. The clinical symptom induced by NADC-20 
includes clinical fever (≥40°C), listless, anorexic and loss of body weight. To explore if JXA1-R 





was monitored daily after NADC-20 challenge. As shown in Fig.6.1A, after NADC-20 
challenge, the average of body temperature in vaccinated pigs was below clinical fever (≥ 40°C), 
and the body temperature of unvaccinated and NADC-20 challenged pigs developed high fever 
at 1, 5, 7, 8 and 9 DPC with a mean body temperature above 40°C, Therefore, the vaccination 
protect pigs from developing a clinical fever induced by NADC-20.  
The body weight gain of pigs was monitored every week after vaccination and viral challenge. 
The body weight gain of vaccinated pigs was significantly lower than that of unvaccinated pigs 
three weeks post vaccination (Fig.6.1B). After NADC-20 challenge, the unvaccinated pigs 
showed slower growth rates, while vaccinated pigs had steady weight gain during the challenge 
period. Field HP-PRRSV was previously reported to lead to significant body weight loss [9], 
however, this report shows the first evidence that HP-PRRSV vaccine can also cause reduced 
body weight gain in pigs.  
6.3.2 JXA1-R MLV Immunized pigs are protected from NADC-20 challenge and have 
reduced viremia and tissue damage compared with unvaccinated pigs 
The PRRS viral load in the blood was measured every week after vaccination and every 3 days 
after challenge. Consistent with previous studies [13], vaccinated pigs developed the highest 
level of viremia at 14 DPV, and then virema went to undetectable levels by 28 DPV (Fig.6.2A). 
At 3 DPC, the circulating viral load in the serum was at similar levels in all pigs NADC-20 
challenged at 3 DPC. However, by 7DPC, the viremia level in unvaccinated pigs was 
dramatically increased and was significantly higher than vaccinated pigs, in which viremia 
dropped to undetectable level. These results show that JXA1-R-MLV immunized pigs were 
protected from NADC-20 challenge as evidenced by reduced viremia. 
 
The gross lung score was evaluated at necropsy. The pathology scores in unvaccinated and 
NADC-20 challenged pigs were significantly higher than vaccinated pigs (Fig.6.2B). 
Interestingly, the lung scores in unvaccinated/unchallenged control pigs were significantly higher 
compared with vaccinated groups (Fig.6.2B). We suspect that the control pigs were infected with 
vaccine strain of PRRSV when they were comingled with vaccinated pigs on 28 DPV (data not 
shown). Indeed, qPCR results showed a very low level of PRRSV RNA (~1000 copy number 





level of RNA at 6DPC. Consistent with qPCR result, ELISA antibody titer in this group became 
positive at 9 DPC (s/p≥0.4, Fig.6.3A) and the scores of histopathological lung and lymph node 
(Fig.6.2C, D) were also higher than vaccinated groups but were lower than unvaccinated and 
NADC-20 challenged pigs. Taken together, histopathological data show JXA1-R-MLV 
vaccinated pigs had significantly lower lesion scores as compared with unvaccinated and NADC-
20 challenged pigs, which again showed that immunized pigs were protected from NADC-20. 
6.3.3 JXA1-R MLV vaccination induces high PRRSV-specific IDEXX ELISA 
antibodies and NADC-20 strain-specific neutralizing antibodies 
To determine the PRRSV-specific antibody response profiles after vaccination and challenge, 
commercial IDEXX PRRS antibody kits were used for the serum samples at each time point. 
Consistent with previous studies, PRRSV-specific antibodies can be detected at 7 DPV with a 
maximum s/p value occurring by 28 DPV (Fig.6.3A). After NADC-20 challenge, the antibody 
titers in vaccinated and NADC-20 challenged pigs increased slightly compared with the 
vaccinated unchallenged pigs, which decreased slightly. The unvaccinated, NADC-20 challenged 
pigs showed a quicker onset of PRRSV antibodies compared with these induced by vaccination 
virus. All serum samples from these pigs became PRRSV-positive with average s/p value of 0.5 
at 6 DPC (34 DPV). Therefore, the above data show that NADC-20 can elicit earlier and higher 
PRRSV-specific antibodies than the JXA1-R MLV vaccine. 
 
The titers of PRRSV neutralizing antibodies directed against NADC-20, JXA1-R (parental 
vaccine strain), and HV-PRRSV (HP-PRRSV strain) were determined at 10 DPC (Fig.6.3B-D). 
The JXA1-R MLV vaccinated pigs showed significantly higher viral neutralizing (VN) titers to 
all strains than unvaccinated pigs, which were undetectable. The vaccinated and NADC-20 
challenged pigs also showed higher VN titers to all three strains of virus than vaccinated without 
challenged pigs, but only the VN titers to HV-PRRSV was significantly different between the 





6.3.4 JXA1-R MLV vaccination increases IFN-β and IL-4 but decreases TNF-α 
secretion in pigs 
Cytokines related to host innate (IFN-α, IFN-β, TNF-α, and IL-8) and adaptive immunity (IL-4, 
IL-10, and IFN-γ) in the serum at 6 DPC and supernatant of lung homogenates at necropsy 
(10DPC) were analyzed by commercial ELISA kits. For the innate cytokines, vaccinated pigs 
generated more IFN-α in the lung sample as compared with unvaccinated pigs, but the difference 
was not statistically significant (Fig.6.4A). Vaccinated pigs also generated significantly higher 
IFN-β but significantly lower TNF-α level in the lung sample (Fig.6.4B, D). The serum IFN-β in 
unvaccinated and NADC-20 challenged pigs was significantly higher than the other three groups, 
which had undetectable levels (Fig.6.4B). Unvaccinated control pigs that became infected with 
vaccine JXA1-R-MLV due to comingling with vaccinated pigs showed significantly higher IL-8 
expression levels in the serum (Fig.6.4C), even though viral load was low.  
 
As for the adaptive cytokines, vaccinated and NADC-20 challenged pigs developed significantly 
higher serum IL-4 levels than all other groups (Fig.6.5A), and serum IL-4 in unvaccinated but 
NADC-20 challenged pigs was also significantly higher than vaccination alone pigs. There was 
no significant difference for IL-10 and IFN-γ expression in the serum and lung samples 
(Fig.6.5B, C). In a recall response, the PBMCs were re-stimulated with NADC-20. Vaccinated 
and NADC-20 challenged pigs generated higher quantities of IFN-γ secreting cells among all 
pigs, but the difference was not statistically significant (Fig.6.5D).  
 
 6.4. Discussion  
As one of the most prevalent diseases in swine, PRRS has caused vast economic losses to the pig 
industry worldwide, and the wide spread of HP-PRRSV in Southeast Asia has caused devastating 
losses to the Asian swine industry. In 2006, HP-PRRSV affected over 2 million pigs with about 
400,000 fatal cases in China alone [3]. Therefore, increased knowledge about the pathogenesis 
and the development of vaccines against HP-PRRSV is necessary for HP-PRRSV-free countries 
in the event of possible transmission. Recently, Porcine Epidemic Diarrhea Virus (PEDV) was 
reported to be found in 12 US states, and the isolated PEDV strains share the highest identity 





US remain unknown, the possibility of HP-PRRSV transmission to other countries outside China 
seems very likely. The availability of Chinese HP-PRRSV vaccines in North America may not 
only act to increase the preparedness of possible transmission of HP-PRRSV to North America 
but also help protect pigs against PRRSV strains native to North America. Therefore, in this 
study, we explored the protection ability of HP-PRRSV vaccine to the North American native 
PRRSV strain NADC-20. 
 
JXA1-R MLV vaccine protected pigs from high fevers induced by NADC-20 as compared with 
the unvaccinated and challenged pigs. As a virulent PRRSV strain, NADC-20 can cause clinical 
fever (≥40°C) at the early stage of infection. Vaccinated pigs showed transient increased body 
temperature in the first four days after NADC-20 challenge (Fig.6.1A). Vaccinated pigs 
eliminated NADC-20 virus in the blood to undetectable levels by 6 DPC, whereas the 
unvaccinated pigs developed the highest level of viremia at this time point (Fig.6.2A). The 
results of gross lung evaluation and histopathology of lung and lymph nodes also showed that 
JXA1-R vaccine was able to protect pigs from NADC-20 challenge, resulting in reduced 
pathology scores (Fig.6.2B-D). Therefore, all above results show that vaccinated pigs were 
protected from NADC-20 challenge. However, vaccinated pigs also showed decreased growth 
rate as compared with unvaccinated pigs before NADC-20 challenge (Fig.6.1B). HP-PRRSV 
field isolates were reported to lead to loss of body weight after infection, but it is the first time 
that HP-PRRSV vaccine was found to decrease pig growth rate. Therefore, the slow body weight 
gain rate caused by vaccination should be taken into consideration before widespread use of the 
HP-PRRSV vaccines.   
 
By 7 DPV, the antibody response against N proteins of PRRSV, as measured by IDEXX ELISA, 
was detected in the vaccinated pigs and increased before NADC-20 challenge (Fig.6.3A). After 
NADC-20 challenge, the IDEXX ELISA antibody titer remained constant, and unvaccinated pigs 
showed PRRSV positive antibodies at 6 dpi. Interestingly, the unvaccinated and NADC-20 
challenged pigs showed earlier onset of ELISA antibody titers as compared with other pigs, 
which could be due to the more virulent character and higher proliferation ability of NADC-20 
over the vaccine strain. Neutralizing antibodies (NA) did not emerge until 28 DPV in vaccinated 





neutralizing ability to NADC-20 and parental strain of vaccine JXA1-R than other groups at 37 
DPV (Fig.6.3B, C). Interestingly, the NA titer of pigs in the vaccinated and NADC-20 
challenged group showed significantly higher titers to HV-PRRSV (Fig.6.3D), a strain of 
Chinese HP-PRRSV rescued from an infectious clone of PRRSV [15]. The enhanced 
neutralizing ability to HV-PRRSV may be due to the disparity of PRRSV strains and the strategy 
of prime (vaccination) and boost (challenge) with another heterologous PRRSV strain could 
generate broader cross-protection to PRRSV field strains. 
 
Cytokines play multiple important roles in modulating host immunity to PRRSV infection. 
Vaccination increased innate cytokine IFN-α and IFN-β expression in the lung tissue (Fig.6.4A, 
B). Working as potent antiviral molecules, IFN-α/β was reported to significantly inhibit PRRSV 
replication and enhance cellular-mediated immunity (IFN-γ responses) [16,17]. However, several 
studies showed that PRRSV had evolved several strategy of expressing viral proteins to 
circumvent type I IFN response, especially to IFN-β [18-20]. Therefore, how to overcome the 
suppression of type I IFNs caused by PRRSV infection is one of priority of PRRSV vaccine 
development. In this study, vaccinated and NADC-20 challenged pigs developed significantly 
higher IFN-β in the lung tissue as compared with unvaccinated pigs after NADC-20 (Fig.6.4B), 
which may partially contribute to less lung damage and the reduced viremia level in the blood 
circulation. In contrast, vaccination decreases TNF-α expression in the lung tissues (Fig.6.4D). 
TNF-α is a proinflammatory cytokine, which plays a very important role in regulation of immune 
responses, fever development (inflammation), and cell apoptosis [21]. The suppression of TNF-α 
expression in the lung correlated well with less lung damage caused by NADC-20, which also 
had significantly lower macro- and histopathological lung scores (Fig.6.2B and C).  
 
As for adaptive cytokines, the expression of IL-4 in the serum was significantly higher in 
vaccinated pigs as compared with unvaccinated pigs after NADC-20 challenge (Fig.6.5A). The 
Th2 cytokine IL-4 is involved in the suppression of pathogen specific Th1 immune response 
[22]. Our previous results and results from others suggest that increased IL-4 expression may 
play a positive role in the immune response and clearance of PRRS virus [13,23]. Our results 
show that vaccinated pigs challenged with NADC-20 PRRSV had increased IL-4 expression as 





by NADC-20 challenge. These results indicate that IL-4 may play a positive role in the humoral 
immune response to the PRRSV infection.  
 
Unvaccinated pigs were infected with vaccine strain of PRRS virus when they were mingled 
with vaccinated pigs at 28 DPV, even though the viremia level in these vaccinate pigs at this 
time point was very low (~ 1000 PRRSV RNA copy number/μl). These results suggest the high 
transmission ability of PRRSV even at such low viremia level. These pigs developed similar 
PRRVS-specific ELISA antibody titers at 6 day post infection (34 DPV) as vaccinated pigs at 7 
DPV (Fig.6.3A).Therefore, vaccination for PRRS via herd immunity should be further explored.  
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Figure 6.1. Body temperature and weight gain. (A) Rectal temperature of pigs was monitored 
daily after NADC-20 PRRSV challenge. (B) Fold body weight gain during the duration of the 
experiment was calculated by considering the weight of the pig on D0 as 1. Each bar represents 






Figure 6.2. Viral load and pathological analysis after NADC-20 challenge. (A) PRRSV viral 
RNA in the serum was determined by qPCR. (B) Gross lung lesion scores present in all lung 
lobes on 10 DPC were scored using a 100 point scale. (C) The lungs were sectioned at necropsy 
(10DPC), blindly examined and given an estimated score of the severity of interstitial pneumonia 
from 0 to 4. (D) Lymph nodes were collected at 10 DPV and sections were blindly examined and 
given an estimated score according to the amount of hyperplasia from 1 to 3. One asterisk 
denotes a statistically significant difference (P <0.05), and two asterisks denote a statistically 





Figure 6.3. PRRSV-specific IDEXX ELISA antibody and neutralizing antibody profiles after 
vaccination and NADC-20 challenge. (A) Serum from pigs was assayed for PRRSV-specific 
antibodies with IDEXX HerdCheck ELISA. The threshold for seroconvertion was set at a 
sample-to-positive (s/p) ratio of 0.4 according to manufacturers’ instructions. (B-D) Serum 
samples were titrated individually in MARC-145 cells for the levels of anti-PRRSV neutralizing 
antibodies on 28 days post vaccination (28 DPV) or 10 days post challenge (37 DPV) determined 
as the highest dilution that inhibited CPE. Data were shown as mean ± SEM for 5 pigs per group. 
One asterisk denotes a statistically significant difference (P <0.05), and “NS” denotes there was 





Figure 6.4. Innate cytokine responses after NADC-20 challenge. Cytokine expression profiles in 
the sera of challenge pigs 6 days post challenge (DPC) and supernatants of lung homogenates 
were tested by quantitative ELISA as shown in (A) IFN-α (B) IFN-β (C) IL-8 and (D) TNFα. 
One asterisk denotes a statistically significant difference (P <0.05), and “NS” denotes there was 





Figure 6.5. Adaptive cytokine responses after NADC-20 challenge. Cytokine expression profiles 
in the sera of challenge pigs 6 days post challenge (DPC) and supernatants of lung homogenates 
were tested by quantitative ELISA as shown in (A) IL-4 (B) IL-10 (C) IFN-γ. (D) PBMCs 
collected at 10 DPC were re-stimulated with NADC-20 strain of PRRSV. IFN-γ-secreting cells 
were then analyzed by ELISpot assay. Data were shown as mean ± SEM for 5 pigs per group. 
One asterisk denotes a statistically significant difference (P <0.05), and “NS” denotes there was 







Chapter 7 - Conclusions and future directions 
The rapid evolution rate of PRRSV worldwide generates countless genetically distinct field 
isolates, which pose a big challenge for current commercial PRRSV vaccines to provide broad 
protection. Studies on the difference of immune responses to homologous and heterologous 
challenge lay an important foundation for the development of effective vaccines and eradiation 
strategies. In chapter 2, by evaluating the differences of immune responses between vaccinated 
and unvaccinated pigs when challenged with homologous or heterologous PRRSV, we 
demonstrate that serum neutralizing antibody titers are associated with PRRSV vaccination-
induced protection against homologous and heterologous challenge.  PRRSV antibody IDEXX 
ELISA is widely used in the field to evaluate the antibody response after vaccination. These 
assays detect antibodies specific for the N protein of virus. In our study, we observed 
discrepancies between the level of protection, as shown by viremia/ lung damage results, and 
high titer of ELISA antibodies indicate anti-N protein antibodies are not predictive of PRRSV 
protection. 
 
MLV vaccinated and KS-06 challenged pigs developed a higher level of VN antibodies to the 
heterologous NVSL97-7895 PRRSV strain, which supports the hypothesis that dual vaccination 
with differing PRRSV strains can generate higher neutralizing antibodies and therefore lead to 
broader cross-protection against diverse PRRSV field strains. Similar observations have been 
reported in influenza virus vaccination strategy studies [1]. Similar strategies have also increased 
protective neutralizing antibodies and cellular immunity in mouse and non-human primate 
models after live vaccine vaccination followed by a boost of DNA vaccine [2,3]. Therefore, a 
strategy involving consecutive vaccinations by two strains of PRRSV vaccines or two types of 
vaccines may increase the protection induced by vaccination.  
 
In our study, we also found the PRRSV-dependent cytokine expression patterns are PRRSV 
challenge-strain specific as shown by increased serum IL-8 after VR-2332 viral challenge and 
increased IL-4 but decreased IFN-a/IL-10 after KS-06 challenge. The cytokine environment 
shapes the host immune responses to PRRSV infection and pigs which clear PRRSV infection 





serum level of inflammatory cytokine IL-8 in vaccinated pigs challenged with homologous VR-
2332 virus was the highest among all treatment groups, which is consistent with previous studies 
which have shown that low level of serum IL-8 is seen in persistent PRRSV infection, and 
elevated IL-8 levels in serum is correlated with the clearance of PRRS virus [5]. However, we 
did observe any changes to serum levels of IFN-γ among the four treatment groups and lower 
levels of IFN-γ was found in fully protected vaccinated pigs challenged with VR-2332 compared 
with partially protected vaccinated pigs challenged with KS-06 strain, which suggests that 
increased IFN-γ expression does not correlate with protection against PRRSV. Therefore, the 
role of IFN-γ in the protection to PRRSV infection needs to be further explored. We did not 
explore the role of IL-1β in mediating host immunity to PRRSV infection in this study. 
 
Different types of adjuvants have been combined with modified live PRRSV vaccines to induce 
vaccination-mediated cross-protection against genetically dissimilar PRRSV strains. These 
adjuvants can enhance the immune responses by different mechanisms such as delivering the 
antigen slowly to the organism (depot effect), increased antigen uptake and presentation to 
antigen presenting cells, recruitment and activation of macrophages and lymphocytes, and 
stimulation of the production of cytokines and chemokines. In chapters 3 and 4, we evaluated the 
efficacy of PRRSV MLV vaccine combined with commercial Montanide
TM
 Gel01 and 
experimental H9e hydrogel peptide adjuvants.   
 
In chapter 3, we found Gel 01-adjuvanted MLV was able to better protect pigs challenged with 
VR-2332 than pigs vaccinated with MLV alone and the protection was due to the higher 
neutralizing antibody titers induced by adjuvanted vaccinations. Additionally, pigs vaccinated 
with the MLV vaccine alone had increased IL-10 production as compared with unvaccinated 
animals and the addition of Gel01 adjuvant acted to decrease IL-10 to levels to at or below 
unvaccinated animals. IL-10 is a potent immunosuppressive cytokine that interacts with a wide 
array of immune cells to inhibit host innate and adaptive immunity [6]. Therefore, removal of 
PRRSV-induced immunosuppressive cytokine IL-10 should be taken into consideration for 






In chapter 4, our results showed that H9e hydrogel is a promising adjuvant candidate for PRRSV 
MLV vaccines since it helps vaccine to improve both host humoral and cellular immune 
responses. Some self-assembling peptides have been successfully used as adjuvants to elicit 
strong antibody response and/or cellular response [7, 8]. As compared with these peptide 
adjuvants, H9e hydrogel has several significant advantages working as an adjuvant over the other 
peptide adjuvants. First, antigens can be encapsulated and protected for delivery by simply 
mixing with H9e hydrogel through various routes of administration, such as intranasal or 
intramuscular, and animal experiments show there were no injection site reactions [9]. Second, 
the release rate of antigen can be controlled by varying the concentration of H9e hydrogel. 
Altering H9e concentration from 0.17%-5% will create different sizes of porous networks, which 
will allow for different rates of antigen release. Third, the mixture of H9e hydrogel and antigen 
remains in liquid form and immediately converts into solid gel once it contacts serum 
components at body temperature. Fourth, its shear-thinning ability allows H9e hydrogel to be 
repeatedly converted from solid to liquid state within minutes, allowing for it to easily pass 
through a needle [10]. As shown in the literature [7-9], the hydrogel/vaccine formulation can 
improve host humoral and cellular immunity. However, the mechanism is hypothesized to 
involve an antigen-slow releasing (depot-effect of adjuvant) in the gel matrix. We measured the 
viral RNA copy numbers in the muscle injection sites and our preliminary data showed that 
PRRS virus did persist in the injection site longer when the virus was mixed with H9e. The other 
potential mechanisms of hydrogel working as an adjuvant need to be further explored. In order to 
gain mechanistic insight, we combined H9e with VV-OVA (recombinant vaccinia virus 
expressing ovalbumin). We found that mice immunized with H9e + VV-OVA generated 
increased pools of the OVA-specific memory CTL population than mice immunized with VV-
OVA alone. Therefore, the hydrogel itself could act as an immune-stimulator or the hydrogel 
could activate certain cell signaling pathways to enhance immune responses. In the future, 
microarray or two-dimension electrophoresis techniques could be used to analyze differences in 
mRNA or protein which may be involved in the host immune responses.  
 
Highly-pathogenic PRRS virus (HP-PRRSV) causes more severe clinical symptoms and more 
extensive tissue tropism than classic PRRSV, which leads to the death at all ages of pigs with 





current PRRSV vaccines are ineffective and a lack of understanding the pathogenesis of viruses 
exists. In chapter 5, we compared the host immune responses elicited by a Chinese HP-PRRSV 
and a virulent American strain NADC-20, and the results showed that HV-PRRSV has 
significantly higher proliferation ability and induced significantly higher cytokine responses 
including IFN-α and IFN-γ, TNF-α, IL-10, which  was consistent with a previous report from 
another research group [11]. In our study, we also found the high proliferation ability of HP-
PRRSV was not associated with the kinetics of PRRSV-specific ELISA antibody response or the 
increase of antiviral cytokines such as IFN-α and IFN-γ.  Therefore, PRRSV ELISA antibody 
titers, IFN-α and IFN-γ levels, which have been widely used to evaluate the protection provided 
by vaccination or infection in clinical trials, need to be examined further.   
 
In chapter 6, we demonstrated that pigs challenged with the North American NADC-20 strain 
were protected by vaccination with Chinese JXA1-R MLV HP-PRRSV vaccines as evidenced by 
reduced level of clinical fever, reduced viremia, and less lung damage. The vaccinated pigs 
developed high titers of neutralizing antibodies to NADC-20. Also, vaccination increased the 
expression of innate cytokines IFN-α and IFN-β in the lung tissue and IFN-α/β was reported to 
significantly inhibit PRRSV replication and enhance cellular-mediated immunity [12, 13]. The 
above evidence of high viral neutralizing antibody titers and increased IFN-α and IFN-β cytokine 
expression may explain the protection provided by HP-PRRSV vaccination. However, the 
vaccinated pigs showed significant body weight loss after vaccination. Therefore, slow body 
weight gain rates caused by vaccination should be taken into consideration before use of the HP-
PRRSV vaccines in the US.  
 
Since Chinese JXA1-R MLV HP-PRRSV vaccines led to reduced body weight gain after 
vaccination, reduced vaccine load may eliminate the vaccine-induced loss of body weight gain.  
One of our pilot studies showed that pigs vaccinated with a half dose of PRRS MLV combined 
with H9e hydrogel had similar vaccine-induced protection to both homologous and heterologous 
PRRSV challenge (data not shown in the thesis).  In our next experiment, we propose that, by 
adding H9e, we can further decrease the amount of PRRSV vaccines needed to provide 





vaccines may not only reduce the cost of animal vaccination but also decrease risk of the vaccine 
reverting back to virulent strains. 
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